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ABSTRACT OF THE DISSERTATION 
The Role of Apolipoprotein E in Regulating Tau Pathogenesis and Neurodegeneration in a 
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by 
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Washington University in St. Louis, 2018 
Professor David M. Holtzman, Chair 
 
 
APOE4 is the strongest genetic risk factor for late-onset Alzheimer's disease (AD). APOE4 
increases brain amyloid-β (Aβ) pathology relative to other APOE isoforms. However, whether 
APOE independently influences tau pathology, the other pathological hallmark of AD and other 
tauopathies, or tau-mediated neurodegeneration, is not clear. By generating P301S tau transgenic 
mice on either a human APOE knock in (KI) or APOE knockout (KO) background, we show that 
the presence of human APOE, regardless of APOE isoforms, leads to various degrees of brain 
atrophy in 9-month old P301S mice, whereas APOE ablation strongly protects against 
neurodegeneration. In particular, P301S/E4 mice develop significantly more brain atrophy 
compared with P301S/E2 and P301S/E3 mice. Concomitantly, APOE-sufficient P301S mice 
develop ptau staining patterns distinct from P301S/EKO mice, with P301S/E4 mice displaying a 
yet another different pattern from P301S/E2 and P301S/E3 mice that indicates severe 
neurodegeneration. In diseased P301S mouse brain, APOE specifically binds to a high-
molecular-weight tau species and may affect tau pathogenesis through direct APOE-tau 
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interaction. APOE level strongly correlates with ptau levels, and is associated with less soluble 
tau and more insoluble tau. In addition to affecting tau pathology and neurodegeneration, APOE 
has potent immunomodulatory functions. In vitro, E4-expressing microglia produce more 
proinflammatory cytokines following LPS treatment compared with E2- and E3-expressing 
microglia. In vivo, P301S/E4 mice show markedly enhanced neuroinflammation compared to 
P301S/E2 and P301S/E3 mice, whereas P301S/EKO mice are largely protected from the change. 
Co-culturing P301S tau-expressing neurons with mixed glia (80-90% astrocytes + 10-20% 
microglia) derived from human APOE KI and APOE KO mice results in a marked neuronal loss 
in the neuron/E4 co-culture with a concomitant elevation of TNFα level in the medium compared 
to neuron/E2 and neuron/E3 co-cultures, whereas neurons co-cultured with EKO glia exhibit the 
greatest viability with the lowest level of secreted TNFα. In contrast, treatment of P301S neurons 
with recombinant APOE (E2, E3, E4) in the absence of glial cells only leads to a mild neuronal 
impairment compared to the absence of APOE, indicating that APOE regulates 
neurodegeneration in part through glia-mediated neuroinflammation. The effect of APOE on 
glia-mediated neuronal loss requires direct contact between neurons and glia cells, and APOE 
may serve as an opsonin bridging stressed neurons that present ‘eat-me’ signals on cell surfaces 
with microglia by binding to triggering receptor expressed on myeloid cells 2 (TREM2) to 
promote neuronal phagoptosis by microglia. APOE is also required for microglial polarization 
into a neurodegenerative phenotype characterized by a proinflammatory profile and enhanced 
phagocytotic activity. Depleting microglia from mouse brain using the colony-stimulating factor 
1 receptor (CSF1R) inhibitor - PLX3397, rescues neurodegeneration in TE4 mice, but shows no 
impact on TEKO mice, indicating critical roles of microglia in neurodegeneration regulated by 
APOE. Reducing APOE levels in P301S mice by overexpressing an APOE receptor, the low-
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density lipoprotein receptor (LDLR), significantly attenuates neurodegeneration and shifts the 
ptau staining towards an early-disease pattern. In addition, LDLR overexpression leads to a 






                   
                      Chapter 1: Introduction 
 
This chapter is adapted from the following manuscript 
Shi Y, Holtzman DM. Interplay between innate immunity and Alzheimer’s disease: APOE and 








1.1    Alzheimer’s Disease 
          Alzheimer’s disease (AD) is the most common cause of dementia accounting for 60%-
80% dementia cases, and currently affects over 30 million people worldwide. It is a devastating 
neurological disorder characterized by severe neurodegeneration and cognitive disabilities that 
eventually lead to death. Two pathological hallmarks stand out in the AD brain: extracellular 
deposition of amyloid plaques consisting predominantly of amyloid-β (Aβ) peptides, and 
intraneuronal accumulation of neurofibrillary tangles (NFTs) comprising aggregated, 
hyperphosphorylated tau protein. AD pathology begins at least 10-20 years prior to clinical 
symptom onset, with Aβ aggregation being the earliest pathological event1. At a later stage, tau 
pathology begins to build up extending from the limbic system to the neocortex, accompanied by  
 increased synaptic/neuronal dysfunction and inflammation. These pathological lesions 
eventually lead to brain atrophy and dementia (Fig. 1).  
         The amyloid hypothesis poses that the initial Aβ accumulation likely initiates downstream 
pathological events2. Aβ peptides are produced via sequential cleavage of the amyloid precursor 
protein (APP), a transmembrane protein highly expressed in the CNS, particularly in neurons. 
The cleavage is carried out by two enzymes, β-secretase (BACE) and γ-secretase. BACE cleaves 
APP outside its transmembrane domain whereas presenilin, the enzymatic component of the γ-
secretase complex, cleaves APP at multiple sites within the membrane to produce Aβ peptides of 
different lengths such as Aβ38, Aβ40, and Aβ42, among which Aβ42 is the most fibrillogenic 
species1. Upon production, Aβ is secreted out of cell and under pathological conditions, Aβ 
aggregates to form large amyloid deposits in the extracellular space of brain parenchyma. These 
amyloid plaques contain multiple Aβ species ranging from Aβ 38-43, where Aβ42 constitutes the 




Figure 1 | Time course of biomarker changes in AD in relation to clinical stages. The first 
pathological event of AD occurs at least 10-20 years prior to the onset of clinical symptoms in cognitively 
normal people with deposition of amyloid plaques in the brain. At ~5 years before clear-cut cognitive 
decline, tau pathology begins to accumulate in the neocortex, roughly around the same time, 
inflammation increases and neuronal and synaptic loss begins to occur, followed by initiation of brain 
atrophy. This period when AD pathologies build up while a person is still cognitively normal is termed 
preclinical AD. Once sufficient neuronal damage and neuronal loss are accumulated, early mild cognitive 
impairment (MCI) becomes clinically detectable. At this time, amyloid deposition has almost reached 
plateau. As dementia progresses to late-stage MCI, NFT formation increases, accompanied with 
exacerbated neuronal and synaptic dysfunction, inflammation, and brain atrophy. When the disease 
progresses to dementia, cognitive deficits becomes severe and deterioration of clinical functions occurs. 
structure (fibrillar plaques) that can be recognized by Congo red and thioflavin-S staining, 
whereas other plaques contain more diffuse Aβ deposits with a non-β sheet conformation (non-
fibrillar or diffuse plaques) that can only be recognized by Aβ antibody staining1. The amyloid 
plaques are often surrounded by swollen, degenerating neurites (dystrophic neurites) 1, but 
otherwise are not associated with notable neurodegeneration.  
          Tau tangles, the other pathological hallmark of AD, develop at a later disease stage and 
highly correlates with neuronal dysfunction.  In the CNS, tau is produced by neurons, but is also 
present at low levels in glia and in the extracellular space3. As a microtubule-binidng protein, tau 
normally locates in the axons of neurons and serves to stablize microtubules. In AD, tau becomes 
hyperphosphorylated, dissociates from microtubules, and transloates from axons to neuronal cell 
bodies and dendrites1. Hyperphosphorylated tau has a tendency to aggregate, forming NFTs in 
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neuroanl cell bodies and dystrophic neurites. Strong evidence show that tau pathology 
contributes to clinical progression of AD. 
          Alzheimer’s disease can be divided into two major categories1. A small percentage (<1%) 
of Alzheimer’s disease is inherited within families in an autosomal-dominant fashion that 
manifests with early dementia onset, typically between age 30 and 60. This form of familial 
Alzheimer’s disease (FAD) is typically caused by mutations in genes affecting Aβ production, 
Aβ42/Aβ40 ratio, or Aβ structure, such as APP, presenilin1 (PSEN1) and presenilin2 (PSEN2). 
Over 99% of Alzheimer’s disease cases occur later in age, typically in people over 65-years old, 
and are referred to as ‘late-onset’ Alzheimer’s disease (LOAD). While there is no identified 
‘cause’ for LOAD, the two most important risk factors are age and genetics. Among the many 
AD risk loci identified to date, APOE is the first identified AD risk gene and remains the 
strongest genetic risk factor for LOAD. 
 
1.2 APOE as a genetic risk factor for Alzheimer’s disease 
           Apolipoprotein E (APOE) is a lipid-binding protein forming lipoprotein particles with 
lipids and cholesterol to mediate their transport in body fluids. Human APOE consists of 299 
amino acids and contains a mid-region receptor-binding domain (aa 136–150) and a C-terminal 
lipid-binding domain (aa 244–272)4. It binds to lipids and cholesterols and delivers them to cells 
via APOE receptor-mediated endocytosis of lipoproteins. Upon uptake, intracellular APOE 
exhibits a significantly longer half-life than the lipids/cholesterols it carries and may either 
slowly go through degradation or be recycled back to the cell surface5. APOE also mediates 
cellular cholesterol efflux in a process called reverse cholesterol transport, where cellular 
cholesterol is transferred to the lipoprotein via ATP-binding cassette transporter (ABCA1)6. 
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APOE has the highest expression in the liver and the CNS. In the brain, APOE is the most 
abundantly produced apolipoprotein, and is synthesized primarily by astrocytes and to a lesser 
extent by microglia7,8. Under stressed conditions, neurons can also produce APOE9. Three 
common APOE alleles (ε2, ε3, and ε4) are present in human populations, with ε3 being most 
prevalent (~77%) and ε2 being the rarest (~8%)4. Each APOE isoform differs from each other by 
a single amino acid at position 112 or 158 (E2-Cys112, Cys158; E3-Cys112, Arg158; E4-
Arg112, Arg158). These differences affect APOE structures, which subsequently affect APOE 
property and functions such as APOE receptor-binding capacity and lipid-binding capability. For 
example, APOE3 and APOE4 bind to low density lipoprotein receptor (LDLR) with >50 folds 
greater affinity than APOE210. Consequently, APOE2 transports lipids with less efficiency and is 
associated with type III hyperlipoproteinaemia. The lipid components of lipoprotein particles 
also differ between APOE isoforms. APOE4 preferentially binds to large, triglyceride-rich very 
low density lipoprotein (VLDL) particles in the plasma and is associated with a modestly 
increased risk for cardiovascular disease4, whereas APOE2 and APOE3 have a preference for 
small, cholesterol- and phospholipid-enriched high density lipoprotein (HDL)11. In the brain 
where only HDL is present, the sizes of APOE particles in the cerebrospinal fluid (CSF) follow 
the pattern of APOE 2/3>APOE3/3>APOE3/4>APOE 4/4 in middle-aged nondemented 
subjects11. Similarly, in older adults, the sizes of CSF APOE lipoproteins follow the pattern of 
APOE4-negative>APOE4-positive11. The preference of APOE4 to bind larger lipoprotein 
particles is believed to be attributable to the presence of Arg at position 112, which affects the 
conformation of the side chain of Arg61, resulting in domain interaction between Arg61 in the 
N-terminal domain and Glu255 in the C-terminal lipid-binding domain, therefore affecting 
APOE lipid-binding capacity12. In addition, APOE levels are also isoform-dependent. APOE 
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level in human in plasma follows the pattern of ɛ2/ɛ2 > ɛ3/ɛ3 > ɛ4/ɛ4 due to the faster turnover 
rate of plasma APOE4 and lower binding affinity between APOE2 and lipoprotein receptors13. 
APOE levels in human CSF and brain parenchyma in relation to APOE isoforms are less clear13. 
Overall, the different properties of APOE isoforms determine their functional differences in 
disease. 
           APOE as an AD risk gene was first reported in 199314. The ε4 allele is a major AD risk 
factor whereas ε2 is protective relative to the ε3 allele. One copy of ε4 increases AD risk by ~3-
fold and two copies by ~12-fold1. The ε4 allele is significantly enriched in AD patients (~15% in 
the general population and ~40% in patients with AD), and ε4-carrying patients show earlier 
disease onset15, heavier brain amyloid-β plaque load16, greater brain atrophy17, and accelerated 
disease progression18 compared to non-carriers. The initial discovery of APOE as an AD risk 
factor was unexpected. As a lipid-carrier regulating lipid homeostasis, APOE was considered to 
be primarily involved in influencing atherosclerosis. In the early 1990s, APOE was found to be a 
constituent of amyloid plaques19,20, yet its significance was not clear until APOE was identified 
as an Alzheimer’s disease risk factor shortly afterwards. The discovery was inspired by two 
converging lines of evidence, the first showing an Alzheimer’s disease linkage at chromosome 
19q1321 where APOE is located, and the second indicating a physical interaction of APOE with 
amyloid-β14. The close link between APOE and amyloid-β in the initial discovery studies has 
largely driven APOE research in the Alzheimer’s disease field along an amyloid-β track.  
 
1.3  APOE and Aβ pathology    
          To date, substantial evidence from animal models has demonstrated APOE affects Aβ 
deposition in a dosage and isoform-specific fashion22-26. In APP transgenic (Tg) mice expressing 
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human APOE in replacement of the endogenous murine APOE, APOE4 strongly exacerbates 
amyloid plaque deposition whereas APOE2 reduces plaque load compared to APOE324,26. 
Genetic ablation of murine or human APOE in Aβ-depositing mice dose-dependently reduces 
fibrillary amyloid plaques22,23. Mechanistically, studies assessing APOE’s effect on Aβ 
fibrilization in vitro have reported contradictory results, which was likely due to inconsistent 
experimental conditions resulting in different lipid components of APOE27. In vivo evidence 
showed that alteration of APOE lipidation status in the brain has a major impact on Aβ 
deposition. ABCA1-deficient Aβ-depositing mice that have reduced APOE lipidation 
demonstrated a marked increase of amyloid deposition28,29, whereas overexpression of ABCA1 
enhanced APOE lipidation and reduced plaque load30. In addition to affecting Aβ aggregation, 
substantial evidence shows that APOE also regulates Aβ clearance. For example, APOE-
deficient Aβ-depositing mice showed a faster Aβ clearance rate from the ISF compared to their 
APOE-sufficient counterpart31. In Aβ-depositing mice expressing human APOE isoforms, 
APOE4-expressing mice exhibited a higher level of ISF Aβ and a lower ISF Aβ clearance rate, 
whereas APOE2-expressing mice showed lower levels of ISF Aβ and a faster Aβ clearance rate 
compared to APOE3-expressing mice26. This isoform-dependent effect of APOE on ISF Aβ 
clearance was observed at an early age well before plaque accumulation occurs, indicating an 
inherent capacity of APOE isoforms to regulate ISF Aβ clearance. 
          While the role of APOE in regulating Aβ pathogenesis has been well documented, 
accumulating evidence shows that Aβ pathology poorly correlates with clinical symptoms or 
tissue loss32,33. Extensive amyloid plaque deposition can build up in normal aged brains without 
causing overt neurodegeneration or dementia. Therefore, whether APOE influences AD solely 
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by affecting Aβ pathogenesis is questionable. There may be Aβ-independent mechanisms 
through which APOE impacts AD. 
 
1.4    APOE and tau pathology 
          Contrary to Aβ, accumulation of pathological tau in the AD brain and in primary 
tauopathies strongly correlates with clinical signs and neurodegeneration3-5. The concurrence of 
tau pathology and neuronal injury in the timeline of AD disease progression, and substantial 
evidence from clinical and animal studies strongly suggest tau pathology contributes to neuronal 
dysfunction. 
          Interestingly, Recent GWAS studies show a strong and significant association of APOE 
with CSF tau and p-tau after correcting for the effect of APOE on Aβ42 levels34,35. In 
frontotemporal dementia (FTD) patients, a large percentage of whom have tauopathy, ε4 allele 
frequency was reported to be significantly elevated36,37, and ε4 carriers have greater atrophy in 
affected brain regions17 as well as exacerbated behavioral deficits38. These data suggest that 
APOE may directly influence tau pathology and tau-mediated neurodegeneration. Early studies 
showed that APOE interacts with human tau in an isoform-specific manner in vitro39,40, 
However, the role of physiologically-expressed APOE in regulating tau pathogenesis and 
associated neurodegeneration independent of Aβ has never been clearly assessed, although 
abnormal overexpression of human APOE4 in neurons, but not astrocytes, has been reported to 
increase tau phosphorylation in mouse brains compared to APOE3 overexpression41,42. In the 
following chapters, we will address the above question in a tauopathy mouse model and 












Chapter 2: APOE modulates neurodegeneration 
in the setting of tauopathy 
 
 
This chapter is adapted from the following manuscript 
 
Shi, Y. et al. APOE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of         







An appropriate mouse model recapitulating tau pathology and tau-mediated neurodegeneration is 
critical for the study. Rodents don’t naturally develop Alzheimer’s disease, nor do they 
accumulate any AD pathologies. However, mouse models developing amyloid plaques or tau 
tangles have been generated by overexpressing mutated human transgenes encoding 
APP/presenilin or tau. Human tau is encoded by the microtubule-associated protein tau gene 
(MAPT). Six major tau isoforms generated by alternative splicing are present in the adult human 
brain. These isoforms differ by the number of an N-terminal insert consisting of 29 amino acids. 
Isoforms containing 0, 1 or 2 inserts are defined as 0N, 1N and 2N respectively. Isoforms are 
also categorized based on the presence of three or four C-terminal repeat domains (3R or 4R 
respectively). In the adult human brain, the level of 3R and 4R tau are roughly equal, whereas 1N 
tau is more abundant relative to 0N and 2N tau43. Compared to 3R tau, 4R tau is shown to have 
higher susceptibility to phosphorylation and aggregation44. In this thesis work, we utilized a tau 
transgenic (Tg) mouse model overexpressing 1N4R human tau carrying the P301S mutation 
found in FTD patients. These mice develop tau pathology around 4-5 months of age, but are free 
of Aβ pathology. Unlike Aβ-depositing mouse models that don’t show overt neurodegeneration, 
P301S tau Tg mice demonstrate visibly distinct severe brain atrophy at 9-12 months of age, 
therefore serving as a good model to assess tau pathology and tau-mediated neurodegeneration. 
          To study the isoform-dependent effects of human APOE on tau and neurodegeneration, 
human APOE knock in (KI) mice are utilized. These mice express human APOE under the 
endogenous murine APOE promoter, therefore representing the physiological pattern of APOE 
expression regarding APOE levels and expressing cell types. This is crucial as overexpressing 
APOE can induce significant metabolic changes that affect experimental outcome, and non-
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physiological APOE expression by specific cell types other than glia, such as neurons, can cause 
proteolytic processing of APOE with generation of cytotoxic fragments23, which would confound 
the results. To assess the APOE dosage effect, APOE knockout (KO) mice are also utilized. 
Through a series of genetic crossing, the endogenous murine APOE of P301S mice are either 
replaced by human APOE isoforms (E2, E3, E4) or deleted. Neurodegeneration was first 
analyzed in these mice and compared across different APOE genotypes. 
          Extending the analysis from mouse models to human, we also assessed neurodegeneration 
affected by APOE genotypes in patients with primary tauopathies. Primary tauopathy is a class 
of neurodegenerative diseases characterized by accumulation of pathological tau in the brain, 
including Pick’s disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration 
(CBD), argyrophilic grain disease, primary age-related tauopathy, and a recently characterized 
entity called globular glial tauopathy45. The nomenclature of primary tauopathies overlaps 
significantly with the modern classification of frontotemporal lobar degeneration (FTLD), also 
frequently referred to as frontotemporal dementia (FTD). Approximately 40% of FTD patients 
manifest tau pathology, whereas the rest are characterized by other pathological deposits 
including TAR DNA-binding protein 43 (TDP-43), fused in sarcoma (FUS), and other unknown 
ubiquitinated proteins46. In addition to these predominant pathologies, some patients also harbor 
certain degrees of co-pathologies such as Aβ and α-synuclein pathologies. Although a previous 
study demonstrates exacerbated neurodegeneration in affected brain regions in ε4-carrying FTD 
patients compared to non-carriers, it doesn’t differentiate between patients developing tau 
pathology versus other pathologies, nor do they take into account co-pathologies. We analyzed 
neurodegeneration in a cohort of PSP, PiD and CBD patients, the three most common sporadic 
forms of FTLD-tau. All samples are confirmed by histological staining to possess tau pathology, 
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and the effect of APOE genotype on neurodegeneration is normalized to the co-pathologies in 
each sample. As a proof of concept, we also assessed APOE genotype effect on clinical disease 
progression rate in human AD subjects. Alzheimer’s disease is deemed as a secondary tauopathy, 
and the disease progression is believed to be driven by tau-mediated neurodegeneration. 
 
2.2 Experimental procedures 
Animals. Human APOE2, APOE3, and APOE4 knock-in mice (C57BL/6) were provided by Dr. 
Patrick M. Sullivan (Duke University) and APOE knockout mice (C57BL/6) were purchased 
from The Jackson Laboratory (#002052). P301S tau transgenic mice (The Jackson Laboratory, 
#008169) on a B6/C3 background expressing human P301S 1N4R tau driven by PrP promoter 
were crossed to human APOE KI mice to generate P301S hE/hE mice for all three APOE 
isoforms, which were then crossed to APOE KO mice to generate P301S hE/- mice. Separately, 
APOE KI mice were crossed to APOE KO mice to generate hE/- mice. P301S hE/- mice were 
then crossed with hE/- mice to generate P301S hE/hE, P301S hE/- and P301S -/- littermates for 
all three APOE isoforms. Only P301S hE/hE and P301S -/- male mice were used for analysis. 
All tau transgenic mice for final analysis were kept at the same generation and had ~90% 
C57BL/6 background by congenic test. P301S APOE KO mice derived from three APOE 
isoforms showed no difference in analysis and were combined as one single group (TEKO). WT 
mice were purchased from Charles River Laboratories (#027) on a C57BL/6 background and 
were bred separately from the P301S/APOE mice. Due to a slightly different background of the 
WT mice, we did not perform statistical analysis comparing WT to other mice. All animal 
procedures and experiments were performed under guidelines approved by the animal studies 
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committee at Washington University School of Medicine. Sample sizes were chosen based on 
estimates to provide 80% power to see significant differences of 20% or greater. 
Volumetric analysis. Every sixth coronal brain section (300 um between sections) starting 
rostrally at bregma +2.1mm to the dorsal end of the hippocampus at bregma -3.9 mm were 
mounted for each mouse. All mounted sections were stained with 0.1% Sudan black in 70% 
ethanol at RT for 20 min, then washed in 70% ethanol for 1 min, 3 times. The sections were 
finally washed in Milli-Q water for 3 times and coverslipped with Fluoromount. The stained 
slices were imaged with the NanoZoomer and areas of interest were traced and measured in each 
slice using the NDP viewer. The volume was calculated using the following formula: volume = 
(sum of area) * 0.3 mm. For hippocampus and posterior lateral ventricle, quantification started 
from bregma -1.1 and ended at bregma -3.9. For piriform/entorhinal cortex, quantification started 
at bregma -2.3 and ended at bregma -3.9. 
Neuronal layer thickness measurement. Three sections (bregma -1.4, -1.7, and -2.0 mm) from 
each mouse were mounted and stained in cresyl violet for 5 min at RT. The slices were then 
sequentially dehydrated in 50%, 70%, 95% (3 times) and 100% ethanol (twice) for 1min, then 
cleared in xylene for 4min (twice), and coverslipped in cytoseal60 (Thermo Fisher Scientific, 
8310-16). The thickness of the CA1 pyramidal cell layer and dentate gyrus granular cell layer 
were measured by drawing a scale perpendicular to the cell layer at two spots in all three slices 
and taking the average value for each mouse. 
Study of neurodegeneration in human primary tauopathies. We searched the University of 
California, San Francisco Neurodegenerative Disease Brain Bank database for patients with 
APOE genotyping and a pathological diagnosis of CBD, Pick’s disease, or PSP, the three most 
common sporadic forms of FTLD-tau. Authorization for autopsy was provided by patient’s next-
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of-kin, and procedures were approved by the UCSF Committee on Human Research. We 
constrained our search to patients autopsied since 2007, when systematic, prospective recording 
of neuropathological findings began. Such data were available from 29 patients with CBD, 17 
with Pick’s disease, and 33 with PSP. Demographics and relevant variables are shown in Table 
2.1.  
          Postmortem brains were processed as previously described47. Fixed tissue slabs were 
dissected into blocks representing dementia-relevant brain regions, embedded in paraffin wax, 
and cut into 8 microns-thick sections. Regional neurodegeneration was assessed using 
hematoxylin and eosin-stained sections.  Neuronal loss, astrogliosis and microvacuolation were 
semi-quantitatively graded as absent (0), mild (1), moderate (2) or severe (3). A similar scheme 
was used to rate Aβ deposits (neuritic plaques, diffuse plaques and vascular amyloid-beta 
deposits)48, tau inclusions (neurofibrillary tangles, Pick bodies, globose tangles, neuronal 
cytoplasmic inclusions (other than those listed previously), tufted astrocytes, thorny astrocytes, 
astrocytic plaques, neuropil threads, and other glial cytoplasmic inclusions), α-synuclein 
inclusions (Lewy bodies and Lewy neurites), and TDP-43 inclusions (neuronal intranuclear 
inclusions, neuronal cytoplasmic inclusions, dystrophic neurites, glial cytoplasmic inclusions). 
Composite scores of neurodegeneration (ND score) [(microvacuolation + astrogliosis) / 2) + 
neuronal loss] and for tau, Aβ, α-synuclein, and TDP-43 were generated for each region by 
summing scores across inclusion types for each pathological protein.  
          We limited analyses to regions that had been stained for all four pathological proteins. 
This approach yielded a total of 609 regional assessments across the 79 patients, with an average 
of 8 regions per patient.  Hippocampal CA1-4, subiculum, dentate gyrus and entorhinal cortex 
were the most commonly assessed regions and available in 72 of 79 patients. Additional regions 
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available from no less than 15 patients included midbrain subregions (oculomotor nucleus, 
tectum, periaqueductal grey, dorsal raphe and substantia nigra); anterior cingulate cortex; and 
middle frontal gyrus (Table 2.1). A linear mixed effects model conducted at the brain regional 
level was used to determine the influence of multiple predictors on composite neurodegeneration 
scores.  APOE ε4 carrier status was used as the binary predictor of interest; additional fixed 
effects in the model included tau, Aβ, TDP-43, and α-synuclein composite scores; sex; age; 
pathological diagnosis; rater; and brain region. Patient identity was modeled as a random effect. 
The primary hypothesis was that possession of an APOE E4 allele would be associated with 
greater regional neurodegeneration after controlling for tau pathological burden and other 
relevant predictors.       
Analysis of clinical disease progression in human AD patients. Participants from this study 
are part from two different longitudinal studies, the Knight Alzheimer’s Disease Research Center 
(ADRC) at Washington University and the Alzheimer's Disease Neuroimaging Initiative 
(ADNI*). All procedures were approved by the Washington University Human Research 
Protection Office, and written informed consent was obtained from each participant.  
The recruitment, assessment, and exclusion criteria methods for the Knight ADRC study has 
been published previously49,50. In the case of the ADNI study, further information was previously 
described51. Knight ADRC individuals were evaluated by Clinical Core personnel at Washington 
University and in the case of ADNI, each local site was in charge for the evaluation of local 
participants51,52. Briefly, cases received a clinical diagnosis of AD in accordance with the 
standard criteria53 and presence or absence of dementia. The severity of dementia was staged 
with the Clinical Dementia Rating (CDR) where 0 indicates cognitive normality, 0.5 is defined 
as very mild dementia, 1 is mild dementia, 2 is moderate dementia, and 3 is severe dementia54. 
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The scores in each of the six cognitive and functional domains surveyed by the CDR are summed 
to yield a Sum of Box scores (CDR-SB) ranging from 0 (no impairment) to 18 (maximal 
impairment)55. Sample selection was done as follow: only participants that had an AD diagnosis 
at the last visit and had a CSF profile compatible with AD were included in our analyses. Non-
AD dementia was excluded, as well as individuals in which the CDR at last assessment was 
equal to 0. Individuals with diagnoses of neurological diseases other than AD were excluded. 
Not informative longitudinally measured CDR-SB was removed for each participant. After 
removing the non-informative data points only individuals with at least 1.5 year of follow-up 
were included. A total of 592 participants were included in the analyses.    
          Statistical analysis was carried out using R statistical software and the packages nlme was 
used for linear mixed model. A linear mixed-model repeated measure framework was used to 
account for correlation between repeated measures in the same individual. Disease progression 
was modeled as follows: 
          
Where: Y was CDR-SB, the change in CDR Sum of Boxes per year baseline CDR, baseline Age, 
Gender, follow-up time, level of education, and, to avoid the possibility of spurious association 
due to population substructure, the two first principal components scores were included as 
covariates.   
          * A portion of the human AD data were obtained from the Alzheimer’s Disease 
Neuroimaging Initiative database (http://adniloni.usc.edu). The ADNI was launched in 2003 as a 
public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary 
goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), biological 
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markers, and clinical and neuropsychological assessment can be combined to measure the 
progression of mild cognitive impairment (MCI) and early AD. For up-to-date information, see 
www.adni-info.org.     
Statistical analysis. Unless explicitly stated, all mouse and cell culture data were shown as mean 
± SEM. Differences between groups were evaluated by one-way analysis of variance tests with 
post hoc Tukey’s multiple comparisons tests. For all experiments, data normality was analyzed 
using D’Agostino-Pearson omnibus normality test. For data not following normal distribution, 
Kruskal-Wallis test with Dunn’s multiple comparisons test was performed for statistical analysis, 
and was stated in the figure legend. GraphPad Prism version 6.00 for Windows (GraphPad 
Software, La Jolla, CA) was used for these analyses and creation of the plots. For statistical 
analysis of the p-tau staining pattern distribution, two-sided Fisher’s exact tests were performed 
using the “fisher.test” function in R version 3.4.0 (The R Foundation for Statistical Computing) 
for all four TE groups together as well as for individual comparisons between each two groups. 
 
2.3 Results 
2.3.1   APOE potently modulates neurodegeneration in P301S mice 
To determine whether the presence of APOE or human APOE isoforms affect tau-mediated 
neurodegeneration, we performed brain volumetric analysis in 9-10 months old P301S mice on 
either a human APOE KI or KO background, designated as TE (Tau/APOE) mice. We found that  
the presence of APOE, regardless of isoforms, led to various degrees of brain atrophy in the 
hippocampus, piriform/entorhinal cortex, and amygdala, brain regions where tau pathology  
accumulates in this model, and was accompanied by significant lateral ventricular enlargement 




Figure 2.1 | APOE4 exacerbates neurodegeneration in aged P301S mice whereas genetic 
ablation of APOE is protective. a, Representative images of 9-10 months old wild type (WT) and TE 
mouse brain sections stained with Sudan black b, Volumes of the piriform /entorhinal cortex, 
hippocampus, and posterior lateral ventricle in 9-10 months old WT and TE mice (WT: n=8, TE2: n=22, 
TE3: n=21, TE4: n=32, TEKO: n=30). Data expressed as mean ± SEM, One-way ANOVA with Tukey’s 
post hoc test (two-sided) was used for all statistical analyses except Kruskal-Wallis test with Dunn’s 
multiple comparisons test (two-sided) was used for posterior LV volume analysis. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. Ent: Entorhinal cortex, Piri: Piriform cortex, LV: Lateral ventricle. 
P301S E2/E2 (TE2) and P301S E3/E3 (TE3) mice (Fig. 2.1). Strikingly, the absence of APOE in 
P301S mice (TEKO) largely attenuated the damage compared to P301S mice expressing human 
APOE, and almost completely abolished ventricular dilatation (Fig. 2.1), imposing a strong 
protective effect.  
          The granule cell layer in the dentate gyrus (DG) (Fig. 2.2 a) and the pyramidal cell layer in 
the CA1 region (Fig. 2.2 b) were noticeably and significantly thinner in TE4 mice, and the 
thickness correlated highly with hippocampal volume (Fig. 2.2 c, d), indicating that the brain 
atrophy is likely mediated by neuronal loss. Importantly, no brain atrophy or brain volume  
difference among APOE genotypes was observed in 3-month old TE mice (Fig. 2.3) prior to 
overt tau pathology onset or in 9-month old non-tau transgenic APOE KI mice (Fig. 2.3), 
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indicating that tau pathology is required to induce neurodegeneration and to reveal APOE 
genotype effect on neurodegeneration. 
 
Figure 2.2 | Degrees of hippocampal neuronal loss correlate with hippocampal volume. 
a, b, Thickness of the granule cell layer in the dentate gyrus (DG) and the pyramidal cell layer in CA1 
respectively in 9-month old WT and TE mice with cresyl violet staining (WT: n=7, TE2: n=14, TE3: 
n=11, TE4: n=17, TEKO: n=16). Data expressed as mean ± SEM, One-way ANOVA with Tukey’s post 
hoc test (two-sided). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. c, d, Correlation of DG/CA1 
neuronal layer thickness with hippocampal volume, n=62 biologically independent animals. Pearson 




Figure 2.3| No brain atrophy or brain volume differences in 3-month old TE mice or 9-month old 
non-tau transgenic mice. a, Representative images of 3-month old TE mouse brains (WT: n=10, TE2: 
n=10, TE3: n=10, TE4: n=10, TEKO: n=11) b, Quantification of the piriform/entorhinal cortex, 
hippocampus, posterior lateral ventricle volume in 3-month old TE mice. c, Representative images of 9-
month old non-tau transgenic mouse brains (WT: n=9, E2: n=8, E3: n=12, E4: n=14, EKO: n=9). d, 
Quantification of the piriform/entorhinal cortex, hippocampus, posterior lateral ventricle volume in 9-
month old non-tau transgenic mice. Data expressed as mean ± SEM, One-way ANOVA with Tukey’s 
post hoc test (two-sided) was used for statistical analysis. Kruskal-Wallis test with Dunn’s multiple 
comparisons test was performed for posterior LV volume analysis. 




To investigate whether the pro-neurodegenerative effect of APOE4 also manifests in human 
primary tauopathies, we assessed post-mortem regional neurodegeneration severity in relation to 
APOE genotype in individuals with a primary diagnosis of corticobasal degeneration (CBD), 
Pick’s disease, and progressive supranuclear palsy (PSP), the three most prevalent sporadic 
primary tauopathies. Possession of an ε4 allele was associated with more severe regional 
neurodegeneration (linear mixed effects model, estimate 0.31, p=0.035, 95% CI [0.02, 0.59]) 
after controlling for age, sex, diagnosis, rater, Aβ deposition, Lewy body disease, tau burden, and 
TDP-43 inclusion burden (Table 2.1). In addition, we demonstrated greater regional 
neurodegeneration as a function of tau burden (estimate 0.17, p<0.001. 95% CI [0.14, 0.20]) and 
TDP-43 proteopathy (estimate 0.22, p=0.003, 95%CI [0.07, 0.37]). Aβ deposition, in contrast, 
was associated with less severe neurodegeneration (estimate -0.08, p=0.044, 95%CI [-0.15, -
0.002]), whereas Lewy body disease, which was relatively uncommon in this cohort, showed no 
effect (estimate -0.01, p=0.87, 95% CI [-0.17, 0.15]) (Table 2.1).  
 
2.3.3   APOE4 accelerates disease progression in AD subjects 
We additionally analyzed disease progression in relation to APOE allele status in a cohort of 
CSF biomarker confirmed individuals with symptomatic AD, who invariably possess Aβ 
deposition and usually have tau pathology. We found possession of the ε4 allele was associated 
with significant higher rates of clinical disease progression (p=0.02) in a dose-dependent manner. 
Individuals with one ε4 allele progressed 14% faster than non-carriers and those with two ε4 
alleles progressed 23% faster (Fig. 2.4). Overall, these findings provide converging evidence in 




Table 2.1| Possession of an ε4 allele exacerbates regional neurodegeneration in human primary 
tauopathies. a, Demographics and relevant variables of patients. Brain regional neurodegeneration was 
analyzed using post mortem neuropathological data from a collection of 79 human primary tauopathy 
patients with sporadic FTLD-tau: 29 with corticobasal degeneration (CBD), 17 with Pick’s disease, and 
33 with progressive supranuclear palsy (PSP). Among these patients, 19 were ε4 carriers. b, Brain regions 
used for analysis. 
 
 
Figure 2.4| Possession of ε4 allele accelerates the 
rate of disease progression in AD patients. Disease 
progression rate in a cohort of 592 CSF biomarker 
confirmed individuals with symptomatic AD from two 
different longitudinal studies, the Knight Alzheimer’s 
Disease Research Center (ADRC) at Washington 
University and the Alzheimer's Disease Neuroimaging 
Initiative (ADNI). Data generated based on the 





Despite extensive animal research investigating roles of APOE in Aβ pathogenesis, effects of 
APOE on neurodegeneration, one of the most important readouts in AD, has rarely been 
assessed, and has never been clearly demonstrated, likely due to lack of prominent 
neurodegeneration in amyloid-depositing mice. We found APOE strongly affects 
neurodegeneration in the setting of tauopathy in the absence of Aβ pathology, suggesting that the 
effect of APOE on AD may be partially mediated by APOE modulating tau-mediated 
neurodegeneration independent of Aβ. Importantly, the effect of APOE4 on exacerbating 
neurodegeneration recapitulates in primary tauopathy patients, providing strong supports to the 
animal study. 
          The protective effect of APOE-deficiency on neurodegeneration in the setting of tauopathy 
is unexpected, given that APOE serves nutritional purposes for delivering lipids/cholesterols as 
building bricks for neurons. This effect is likely due to APOE affecting tau pathogenesis, which 
further influences neurodegeneration. On the other hand, pathological tau accumulation triggers 
chronic neuroinflammation, which is another hallmark of AD in addition to Aβ and tau 
pathologies. As a common feature for many neurodegenerative diseases, chronic 
neuroinflammation is not only a consequence of neurodegeneration, but also actively contributes 
to neuronal death. Intriguingly, APOE itself is a potent regulator of immune response. Therefore, 
APOE regulating neuroinflammation may constitute another pathway through which it affects 
neurodegeneration. Effects of APOE on tau pathogenesis and neuroinflammation will be 














Chapter 3: APOE directly regulates tau 





This chapter is adapted from the following manuscript 
 
Shi, Y. et al. APOE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of         







Early studies show that APOE isolated from human plasma binds to recombinant tau in an 
isoform-specific fashion in vitro. APOE3, but not APOE4, forms SDS-stable complexes with 
tau39,40. In addition, APOE immunoreactivity is found to colocalize with neurofibrillary tangles19. 
However, few studies haven followed up to investigate the APOE-tau connection. One group 
showed that artificial overexpression of APOE in neurons induced APOE fragmentation, leading 
to the generation of neurotoxic C-terminal truncated APOE fragments that induce tau 
phosphorylation by activating the extracellular signal-regulated kinase (Erk) 41,42. APOE4 
overexpression was found to result in a significantly higher level of APOE fragmentation and 
greater tau phosphorylation compared with APOE341,42. Other data shows enhanced murine tau 
phosphorylation in APOE4 KI mice that develop Aβ pathology compared to their APOE3-
expressing counterparts56. The effect is likely linked to exacerbated Aβ pathology in the presence 
of APOE4, as Aβ pathology has been reported to induce tau pathology57. However, whether 
physiologically expressed APOE affects human tau pathogenesis independent of Aβ is still not 
clear. Recent GWAS studies showing APOE association with CSF tau and ptau independent of 
Aβ34,35 and the linkage of APOE with primary tauopathies17,36-38 suggest that APOE may directly 
regulate tau pathogenesis.  
          The development of neurofibrillary tangles in the AD brain follows a characteristic 
progression pattern permitting the differentiation of tau pathology into six stages: starting from 
the trans-entorhinal cortex, going through the hippocampus and association cortices, and finally 
proceeding into the primary neocortex58,59. In the brain, tau is primarily an intracellular neuronal 
protein, but is normally secreted into the interstitial fluid (ISF) of the brain3 and is believed to 
transmit tau pathology in a prion-like manner60. The prion hypothesis posits that tau aggregates 
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escape the cell of origin and enter adjacent and synaptically connected cells, where they seed 
new tau aggregation. In vitro experiments demonstrate aggregated tau can transfer between co-
cultured cells61-63 and seed tau aggregation in the newly accessed cells47,49. In vivo, restricted 
P301L human tau expression in the entorhinal cortex of WT mice induced tau pathology in 
synaptically connected brain regions64,65. Injection of brain homogenates from AD patients66 as 
well as from P301S human tau Tg mice67 into the brain of wild-type human tau-expressing mice 
induced assembly of  human tau into filaments and spreading of pathology. Similar effects were 
observed when injecting recombinant full-length P301S tau fibrils or truncated P301L tau fibrils 
into P301S human tau Tg mice, which caused rapid induction of NFT-like inclusions that 
propagated from injected sites to connected brain regions in a time-dependent manner68.  
         The prion-like property of pathological tau to propagate in brain structures in a hierarchical 
fashion provides a potential mechanism through which APOE may affect tau pathology. Cellular 
entry of aggregated tau is mediated by heparan sulfate proteoglycans (HSPG)-mediated 
macropinocytosis69. Importantly, HSPG is also a major receptor for APOE. It is universally 
expressed on cell surfaces along with other principal APOE receptors including low-density 
lipoprotein receptor (LDLR) and LDLR-related protein 1 (LRP1) to mediate APOE binding and 
cellular uptake. The abundance of APOE in the ISF and its potential interaction with tau may 
alter the behavior of tau aggregates in the extracellular space. APOE may bind to tau aggregates 
and affect tau uptake by neurons and other brain cell types via interaction with APOE receptors. 
Depending on the cellular routes of tau entry and the targeting cell types, both tau seeding and 
tau clearance may be affected. In addition, APOE binding to tau may alter the kinetics of tau 
aggregation and tau seeding capacity. Given the possibilities of APOE to be involved in 
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regulating tau pathogenesis, I assessed tau pathology in the TE mice via a combination of 
biochemical and immunohistochemical approaches. 
           
3.2 Experimental procedures 
Immunohistochemistry. The left hemi-brain of each mouse was sectioned coronally at 50 µm 
using a freezing sliding microtome. Three sections from each mouse (300 um apart), 
corresponding approximately to bregma coordinates -1.4, -1.7, and -2.0 mm respectively, were 
used for p-tau staining described by Yanamandra et al70. Briefly, brain sections were washed in 
Tris-buffered saline (TBS) buffer for 3 times followed by incubation in 0.3% hydrogen peroxide 
in TBS for 10 min at RT. After three washes in TBS, sections were blocked with 3% milk in 
0.25% TBS-X (Triton X-100) for 0.5 h followed by incubation at 4°C overnight with 
biotinylated AT8 antibody (Thermo Scientific, MN1020B, 1:500). The next day, the slices were 
developed using the VECTASTAIN Elite ABC HRP Kit (Vector laboratories) following 
manufacturer’s instructions. Stained sections were imaged by the NanoZoomer digital pathology 
system and pathology was quantified using Image J.  
Brain extraction. Mouse cortex was processed in RAB, RIPA and 70% FA buffer sequentially 
as described previously70 with modifications. Briefly, the tissue was weighed and homogenized 
using a pestle with 10ul buffer/1mg tissue in RAB buffer (100mM MES, 1mM EGTA, 0.5mM 
MgSO4, 750mM NaCl, 20mM NaF, 1mM Na3VO4, pH=7.0, supplemented by protease 
inhibitors (Complete, Roche) and phosphatase inhibitors (PhosSTOP, Roche)). After 
centrifugation at 50,000 × g for 20 min, the supernatant was taken as the RAB-soluble fraction 
and the pellet was dissolved in RIPA buffer (150mM NaCl, 50mM Tris, 0.5% deoxycholic acid, 
1% Triton X-100, 0.1% SDS, 5mM EDTA, 20mM NaF, 1mM Na3VO4, pH 8.0, supplemented 
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by Complete and PhosSTOP) at 10ul buffer/1mg tissue by sonication. After centrifugation at 
50,000 × g for 20 min, the supernatant was taken as the RIPA-soluble fraction. The pellet was 
sonicated in 70% formic acid at 10ul buffer/1mg tissue, and centrifuged at 50,000 × g for 20 min. 
The supernatant was taken as the FA-soluble fraction. All fractions were stored in -80°C until 
analyzed. 
ELISA. Human tau and APOE ELISAs were performed as described previously70. For coating 
antibodies, Tau5 (gift from L. Binder, Northwestern University, Chicago, IL) was used for 
human tau ELISA. For detection antibodies, biotinylated HT7 (Thermo Fisher Scientific, 
MN1000B) was used for tau ELISA. 
RT-qPCR. RNAs were isolated from mouse cortex using RNeasy Mini Kit (QIAGEN,74104), 
and reverse transcribed to cDNA using the high capacity RNA-to-cDNA kit (Applied 
Biosystems, #4387406). Quantitative PCR were performed using Taqman primers and probes 
with Taqman universal PCR master mix (Applied Biosystems, #4304437). 
Analysis of tau seeding activity in brain lysates. Mouse cortex was homogenized in DPBS 
supplemented by Complete and PhosSTOP. Lysates were cleared by centrifugation at 12000rpm 
for 10min and protein concentration was measured by BCA assay. Seeding with the lysates was 
performed using a CFP/YFP-based biosensor HEK cell system kindly provided by Dr. Marc 
Diamond (UT Southwestern) as previously described71. Briefly, the pro-aggregating tau repeat 
domain (RD) carrying the P301S mutation was fused to either CFP (RD-CFP) or YFP (RD-
YFP), and were transduced into HEK cells to generate stable HEK cell lines expressing either 
RD-CFP, RD-YFP or RD-CFP/YFP. RD-CFP/YFP HEK cells were transfected with brain 
lysates containing 1ug protein using lipofectamine 2000 (Invitrogen, #11668027) and cultured 
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for 24h. Cells were then collected and run through flow cytometry to quantify FRET signals 
generated. RD-YFP and RD-CFP HEK cells were used for channel compensation. 
Coimmunoprecipitation. Mouse cortex was homogenized on ice using a pestle with 30ul 
buffer/1mg tissue in DPBS supplemented with 1mM EDTA, 1x protease inhibitors (Complete, 
Roche) and 1x phosphatase inhibitors (PhosSTOP, Roche). The samples were spun down at 
1000g for 10min, and the supernatant was used for experiments. For human APOE 
coimmunoprecipitated with tau, HJ8.5 antibody (in house human tau antibody) was incubated 
with protein G dynabeads (Thermo Fisher Scientific, 10003D) overnight at 4 degree. The next 
day, the beads were washed with PBS for three times. The samples were precleared and 
incubated with HJ8.5-coated dynabeads overnight at 4 degree. After incubation, the beads were 
collected and washed in PBS for three times. Samples were then eluted from the beads with 1x 
western blot loading buffer and boiled for 10min before loading for western blot. HT7B (Thermo 
Fisher Scientific, MN1000B), anti-α-tubulin antibody (Sigma, T5168), and anti-human APOE 
antibody (Abcam, Cat# ab24139) were used to detect human tau, α-tubulin, and human APOE 
respectively. For tau coimmunoprecipitated with human APOE, HJ15.7 (in house human APOE 
antibody) was used as the pulling antibody, and the same set of antibodies were used for 
detection. For interaction between murine APOE and human tau, HJ6.3 (in house murine APOE 
antibody) was used for pulling APOE and HJ6.8B (in house murine APOE antibody) was used 







3.3.1 APOE affects human tau levels in P301S mouse brain 
Human tau levels in brain lysates were analyzed via quantitative ELISA following sequential 
biochemical extraction in RAB (salt buffer), RIPA (detergent buffer) and 70% Formic Acid 
(FA), which contains soluble tau, less soluble tau, and highly insoluble tau respectively. At 3  
 
Figure 3.1 | APOE4 increases brain tau levels likely by affecting tau clearance via the 
autophagy pathway. a, Human P301S tau levels in TE mice were measured by ELISA in RAB, RIPA 
and 70% FA fractions respectively at two time points: 3 months (WT: n=2, TE2: n=15, TE3: n=11, TE4: 
n=12, TEKO: n=16) and 9 months (WT: n=5, TE2: n=14, TE3: n=11, TE4: n=17, TEKO: n=38). b, qPCR 
for human tau in 9month TE mouse cortex (WT: n=5, TE2, TE3, TE4, TEKO: n=7). c, d Nanostring 
analysis for autophagy-related gene expression in (c) 9-month old TE mouse hippocampus and (d) 9-
month old non-tau transgenic APOE KI or APOE KO mouse hippocampus (n=5-6 per group). Data 
expressed as mean ± SEM, One-way ANOVA with Tukey’s post hoc test (two-sided) was used for 
statistical analysis. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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months of age, prior to overt tau pathology onset, TE4 mice had significantly higher tau levels in 
the RAB fraction than other APOE genotypes (Fig. 3.1a). At 9 months of age, when large 
amounts of tau pathology have developed, TE4 mice still had significantly higher tau levels, but 
the elevated tau had changed from being in the RAB to the RIPA fraction (Fig. 3.1a), indicating 
a greater amount of tau in a more insoluble fraction. The higher tau accumulation in TE4 mice 
was not due to differences in tau synthesis assessed by qPCR (Fig. 3.1b). However, we found 
significant changes of autophagy-related gene expression associated with APOE4 in the presence 
or absence of tau pathology (Fig. 3.1c, d), suggesting APOE4 may affect autophagy-mediated 
tau clearance. This is consistent with a previous report of impaired autophagy associated with 
APOE472.  
 
3.3.2 APOE regulates tau pathogenesis in P301S mice 
          Hyperphosphorylated tau, identified by p-tau staining with the AT8 antibody, revealed a 
greater p-tau covered area in 3-month old TE4 mouse hippocampus (Fig. 3.2a, b). While the  
pathological p-tau signal first appeared in the mossy fibers, axons of DG granule cells in the 
hippocampus, TE4 mice also showed more intense DG cell body staining (Fig. 3.2a, c), 
indicating a greater redistribution of pathological p-tau from axons to cell bodies at an early age. 
At 9 months of age, the differences in overall p-tau immunoreactivity between TE mice 
decreased (Fig. 3.3a), with the emergence of four major p-tau staining patterns, designated as 
types 1-4 (Fig. 3.3b). These staining patterns strongly correlated with the level of brain atrophy, 
with type 1 associated with the most preserved brain and type 4 associated with the most 
atrophied brain (Fig. 3.3c), suggesting potential differential toxicity associated with different p-




Figure 3.2| APOE4 increases p-tau pathology and promotes pathological tau redistribution 
from axons to cell bodies in P301S mice at an early age. a, AT8 staining for phosphor-tau in 3-
month old TE mouse hippocampus. Dotted outline highlights the dentate gyrus (DG) granule cell bodies. 
b, c, Quantification of AT8 covered area in the hippocampus (b) and in the DG neuronal cell layer (c) 
(TE2: n=16, TE3: n=10, TE4: n=10, TEKO: n=14). Data expressed as mean ± SEM, One-way ANOVA 
with Tukey’s post hoc test (two-sided). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
2 were primarily enriched in TEKO mice whereas type 3 and type 4 were enriched in P301S 
mice harboring human APOE. In particular, type 4 was enriched in TE4 mice. (Fig. 3.3d). The  
featured distribution of these p-tau staining patterns, which either represent different tau 
structures, or progressively more advanced pathological tau stages, indicate APOE affects either 
tau conformation, or tau pathology progression. 
          To further explore whether the p-tau patterns are associated with different tau structures, 
we assessed the tau seeding activity from frozen brain tissues using a biosensor HEK293T cell 
line that co-expresses CFP and YFP fused to the aggregation-prone repeat domain (RD) of tau, 
which can generate a FRET signal when tau aggregation is induce by exogenously applied tau 
seeds. There was a dramatic increase of tau seeding activity associated with type 2 staining 




Figure 3.3| APOE affects hippocampal ptau staining patterns in 9-month old P301S mice. a, 
Quantification of ptau (AT8) covered area in 9-month old TE mouse hippocampus (WT: n=5, TE2: n=14, 
TE3: n=11, TE4: n=17, TEKO: n=38). b, Four distinct p-tau staining patterns were identified based on 
hippocampal staining features. Type 1 has intense mossy fiber staining as well as diffuse cell body 
staining in the dentate gyrus granule cell layer and CA1 pyramidal cell layer; type 2 has compact and 
dense tangle-like cell body staining primarily in the dentate gyrus granule cells and CA3 pyramidal cells, 
but also has sparse staining in the CA1 region; type 3 has staining primarily in the neuropil of the stratum 
radiatum of the CA region with clear staining of dendrites from pyramidal neurons and only some 
staining in the neuronal cell bodies; type 4 has dense staining over the entire hippocampus, unlike other 
staining patterns, type 4 staining is fragmented, dotted, and grainy. c, P-tau staining patterns were 
associated with different degrees of brain atrophy, n=104 biologically independent animals. d, 
Distribution of the four p-tau staining types in 9-10 months old TE mice (TE2: n=22, TE3: n=21, TE4: 
n=32, TEKO: n=38). Fisher’s exact test, two-sided (All groups: p=3.4e-05, TE2 vs. TEKO: p=0.021, TE3 
vs. TEKO: p=0.0016, TE4 vs. TEKO: p=1.9e-07). e. P-tau staining patterns were associated with distinct 
tau seeding activities. f. Tau seeding activities do not differ between APOE genotypes. g. Type1-type4 
ptau staining patterns are associated with progressively more insoluble tau in the formic acid fraction. 
Data expressed as mean ± SEM, One-way ANOVA with Tukey’s post hoc test (two-sided). *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001. 
APOE genotypes (Fig. 3.3f). Interestingly, despite harboring a higher seeding capacity, type 2 
tau is relatively soluble (Fig. 3.3g), consistent with previous studies showing that tau seeds are 
present in the soluble fraction62. The association of enhanced tau seeding activity with a ptau 
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staining pattern that correlates with less brain atrophy indicates that tau aggregation to some 
extent may be less toxic, likely by trapping diffuse tau oligomers that could potentially be more 
toxic. This is consistent with previous findings showing that neurofibrillary tangles are not 
associated with acute neuronal death73,74. Alternatively, tau seeding may represent an early event 
in tau pathogenesis. Aggregated tau may undergo conformational change, lose its seeding 
capacity, and become more insoluble with higher toxicity over time as disease progresses.  
 
3.3.3 APOE interacts with a specific form of tau, likely hyperphosphorylated 
tau. 
Interestingly, I found that APOE specifically interacts with a particular form of tau in 9month old 
P301S mouse brain lysates. In P301S mice, when neurodegeneration occurs, an additional tau 
band stands out in western blot, which locates on top of the major tau band. This upper tau band 
barely or weakly shows up in brains harboring type1 tau, but is increasingly accumulated in 
brains harboring type2, type3 and type4 tau, with the highest amount present in type4 tau- 
containing brains that demonstrate the highest degree of brain atrophy (Fig. 3.4).   
 
Figure 3.4 | An additional tau band shows up in western blot in diseased P301S mouse 
brains. Western blot for human tau detected by HT7B antibody in 3month old TE mouse brain that 
contains only type1 tau and in 9month old TE mouse brains containing type1-type4 tau respectively. 
 
          As tau hyperphosphorylation is a hallmark of tau pathology and is exacerbated during 
disease progression, the upper tau band likely represents a hyperphosphorylated form of tau. 




Figure 3.5 | Human APOE specifically interacts with the upper tau band in 9-month TE 
mouse brain lysates. a, Co-IP between human APOE and human tau. Brain lysates of 9-month old 
TE3, TE4 and TEKO mice were pulled with a human tau antibody HJ8.5. The eluted samples were 
detected by western blot with the human tau antibody HT7B and a polyclone human APOE antibody. α-
tubulin was used as a loading control. b, Brain lysates of 9-month old TE3, TE4 mice and non-tau 
transgenic E3, E4 mice were pulled with a human APOE antibody HJ15.7. Eluted samples were detected 
by the human tau antibody HT7B and a polyclone human APOE antibody. 
 
 
 (Fig. 3.5) independent of APOE isoforms (data not shown). In APOE-tau 
coimmunoprecipitation (Co-IP) experiments, when APOE was pulled from the lysates, only the 
upper tau band was coimmunoprecipitated with APOE (Fig. 3.5a). Vice versa, when tau was 
pulled from the lysates, only when the upper tau band was present did more APOE 




Figure 3.6 | Murine APOE specifically interacts with the upper tau band in 9-month P301S 
mouse brain lysates. a, Co-IP between mouse APOE and human tau. Brain lysates of 3-month old 
(PS1, type1 tau) 9-month old P301S mice (PS-2, type4 tau) that express endogenous murine APOE and 3-
month old TEKO mice were pulled with a human tau antibody HJ8.5. The eluted samples were detected 
by western blot with the human tau antibody HT7B and a mouse APOE antibody HJ6.8. α-tubulin was 
used as a loading control. b, Brain lysates of 9-month old TE3, TE4 mice and non-tau transgenic E3, E4 
mice were pulled with a human APOE antibody HJ15.7. Eluted samples were detected by the human tau 
antibody HT7B and a polyclone human APOE antibody. 
tau band was observed in P301S mice that express endogenous murine APOE as well (Fig. 3.6). 
These results indicate that APOE may be able to regulate tau pathogenesis through direct APOE-
tau interaction. Intraneuronal accumulation of APOE, either derived from APOE retention from 
endocytosis or de novo APOE synthesis inside neurons in stressed conditions, may bind to newly 
formed hyperphosphorylated tau in early disease and promote tau aggregation and insoluble tau 
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formation, which may in turn cause more cellular stress that induce more hyperphosphorylation 
of tau. Interestingly, impaired APOE4 recycling to the cell surface leading to intracellular 
accumulation of APOE relative to APOE3 has been reported75. Therefore, it’s likely that 
increased level of intraneuronal APOE4 interacts with hyperphosphorylated tau to promote tau 
pathogenesis. On the other hand, high-molecular-weight (HMW), hyperphosphorylated tau 
derived from human AD brains and tauopathy mouse models has been reported to possess high 
seeding capacity and constitutes the tau species that mediates intercellular tau transmission and 
tau seeding within neurons62. Neurons were found to specifically take up this type of tau over 
other low-molecular-weight tau species and be effectively seeded by this HMW 
hyperphosphorylated tau62. This particular tau species likely represents the upper tau band seen 
in the diseased brain. Importantly, the HMW tau is present in the ISF of tauopathy mouse brains 
and in the CSF of human AD patients62,76. Given the abundance of APOE in the extracellular 
space, it is likely that APOE binds to these HMW hyperphosphorylated tau in the ISF and affects 
their uptake by neurons through interaction with APOE receptors. Tau-bound APOE may also 
alter the seeding activity of this tau species by altering its conformation. These aspects may 
collectively influence the spreading of tau pathology and disease progression. Given the faster 
turnover rate of APOE4 relative to other APOE isoforms, it may facilitate tau uptake into 
neurons via APOE receptor-mediated mechanisms and promote pathological tau spreading. 
 
3.4 Discussion 
Here we clearly demonstrated that physiologically expressed APOE directly regulates human tau 
pathogenesis independent of Aβ. In general, the presence of human APOE, particularly APOE4, 
worsens tau pathology relative to the absence of APOE. The effects of APOE on tau pathology 
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strongly correlates with its effects on neurodegeneration, indicating that APOE affects 
neurodegeneration in part by modulating tau pathology that confers neuronal toxicity in a cell-
autonomous manner. The specific interaction between APOE and potentially 
hyperphosphorylated tau is intriguing and suggests that APOE may regulate tau pathogenesis 
through direct interaction with pathological tau. Binding of APOE to hyperphosphorylated tau 
appears to facilitate conversion of tau aggregates from a soluble state to a more insoluble state, 
during which course tau loses its seeding capacity. This may be achieved by APOE scaffolding 
and compacting hyperphosphorylated tau to form dense insoluble structures, likely in an APOE 
isoform-dependent manner. Although being less seeding-competent, these insoluble tau may 
possess stronger neurotoxicity. In addition, potential interaction between APOE and 
hyperphosphorylated tau in the ISF may influence tau uptake by neurons and regulates 
pathological tau propagation in an isoform-specific fashion.  
          To further understand the role of APOE in regulating pathological tau behaviors, I 
performed a full set of experiments assessing the effect of APOE and APOE isoforms on the 
binding, uptake, seeding, spreading, and degradation of aggregated tau both in vitro and in vivo. 
The initial highly replicable observation that APOE markedly promoted cellular uptake of tau 
aggregates eventually turned out to be an experimental artifact due to the rapid and robust 
binding of tau protein to laboratory containers. Experimental designs involving preincubation of 
tau aggregates with APOE in eppendorf tubes led to a drastic loss of tau protein in the absence of 
APOE as a result of tau binding to the tube surface. Surprisingly, the presence of APOE in the 
solution completely abolished tau association with the tube, likely due to APOE coating the tube 
surface to prevent tau binding, or APOE forming a complex with tau aggregates to retain them in 
the solution. This resulted in different amounts of starting tau material left in the tube prior to 
39 
 
cell or animal treatment, leading to the experimental artifacts. Although no clear conclusions 
were reached from these studies, the observation that APOE efficiently prevented tau aggregates 
from binding to container surfaces is novel. All proteins to certain degrees bind to container 
surfaces, and this is particularly true for sticky proteins like Aβ, tau, and α-synuclein. Similar 
effects of APOE on synuclein binding to eppendorf tubes were subsequently recapitulated in the 
lab after my initial finding. It’s highly likely that similar effects of APOE also apply to other 
pathological proteins such as Aβ. Interestingly, this APOE effect has never been reported in 
previously literatures although numerous studies have utilized similar experimental settings to 
study APOE functions on pathological proteins, the results of which may need to be interpreted 
with caution.  
          In addition to a direct impact on tau pathology, APOE may also regulate tau pathogenesis 
via modulating neuroinflammation. It has been well documented that neuroinflammation 
influences tau pathology. In P301S mice, administering an immunosuppressing drug FK506 
from an early age drastically reduces tau pathology77. In 3xTg-AD mice, chronic intraperitoneal 
administration of lipopolysaccharides (LPS) for 6-weeks is shown to induce marked microglial 
activation and promote site-specific tau hyperphosphorylation78. Similarly, deleting the 
microglia-specific homeostatic gene CX3CR1 in htau mice leads to amplified microglial 
activation and enhanced tau hyperphosphorylation /aggregation79,80; whereas overexpressing a 
soluble form of CX3CL1, the ligand for CX3CR1, reduces microglial activation and tau 
pathology in rTg4510 mice81. IL-1 signaling was identified to play a key role in 
neuroinflammation-induced tau phosphorylation by enhancing the activity of tau kinases 
including CDK5/p25, GSK-3β, and p38–MAPK82,83. As briefly mentioned earlier, APOE plays 
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an essential role in immune regulation. Effects of APOE on neuroinflammation may constitute 
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While APOE regulates tau pathology, which may subsequently affect neurodegeneration through 
tau-mediated neurotoxicity in a cell autonomous fashion, the accumulation of pathological tau 
along with degenerating neurons also induce chronic neuroinflammation that constitutes another 
major mechanism of neuronal loss. To date, more than 30 Alzheimer’s disease-risk loci have 
been identified via a combination of genetic linkage, candidate gene, genome-wide association 
studies (GWAS), and whole genome/exome sequencing (WGS/WES) studies84. Of these risk 
loci, over 50% of gene variants validated by functional genomics are implicated in microglial 
and innate immune cell function, including the top two risk genes, APOE and TREM2. In 
addition, epigenomic analysis has shown that Alzheimer’s disease GWAS loci are preferentially 
enriched in enhancer sequences implicated in innate immune processes85. These findings indicate 
an essential role of the innate immune response in Alzheimer’s disease pathogenesis.  
          In the brain, neuroinflammation heavily relies on innate immune responses mediated 
primarily by CNS-resident microglia and also by astrocytes. Prolonged inflammation may induce 
neuronal injury and death via multiple ways. First, activated glia produce toxic substances such 
as reactive oxygen species (ROS) and nitric oxide (NO) that can directly damage or kill neurons; 
second, inflammatory stress and sub-lethal pathological insults can induce stressed-but-viable 
neurons to expose reversible ‘eat-me’ signals such as phosphatidylserine or calreticulin, and be 
phagocytosed and killed by activated microglia via a process called phagoptosis86; third, 
activation of the complement system promotes membrane attack complexes (MAC) formation, 
creating pores on cell membranes to induce cell lysis; fourth, activated microglia can crosstalk 
with astrocytes, inducing reactive astrocytes to rapidly kill neurons via secreted neurotoxic 
factors and loss of neurotrophic function87, and fifth, neuronal NLRP1 (NACHT, LRR and PYD 
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domains-containing protein 1) inflammasome and caspase-1 activation can directly induce 
neuronal injury and death88,89. In addition to a direct effect on neuronal viability, 
neuroinflammation also affects tau pathogenesis, which in turn can influence neurodegeneration. 
Therefore, glia-mediated innate immunity plays a critical role in neurodegeneration and may 
constitute a driving force for disease progression. 
            Intriguingly, APOE itself has been found to be a potent modulator of immune responses. 
The association of APOE4 with a higher innate immune reactivity has long been observed. In 
healthy humans challenged with intravenous LPS infusion, ε4-carriers demonstrate significantly 
higher elevation of body temperature and plasma TNF levels compared to ε4 non-carriers90. 
Similarly, when whole blood isolates from human subjects were stimulated ex vivo with TLR 
ligands, enhanced production of a wide panel of cytokines and chemokines was observed in 
blood from ε4+ donors compared with ε4- donors90. A greater immune response associated with 
the ε4 allele compared to other APOE alleles is also observed in human APOE-targeted 
replacement (APOE-TR) mice and in cultured microglia/macrophages upon LPS stimulation90-92. 
This evidence suggests that the effects of APOE on neurodegeneration may be in part mediated 
by its immunomodulatory function. We therefore investigated this hypothesis in this chapter.            
 
4.2 Experimental procedures 
Primary microglia culture, LPS stimulation and cytokine measurement. Mixed glia culture 
from APOE2, APOE3 and APOE4 KI mice were prepared as described above in DMEM/F12 
medium supplemented with 10% FBS and 5ng/ml GM-CSF. Loosely attached microglia were 
harvested at DIV12 by shaking for 2 hours at 400 rpm and then seeded onto 12-well tissue 
culture plates coated with PLL at a density of 1×106 cells per well. The next day, seeded 
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microglia were washed in serum-free medium (SFM-DMEM/F12 + 0.2% BSA +1x pen/strep) 
and placed in 450 µl SFM. Cells were then treated with 1 ng/ml LPS (Sigma, #L5293) for 24h. 
Medium were collected and spun down at 10,000g for 10 min. Supernatants were collected and 
assayed for mouse TNFα, IL-1α and IL-1β using single cytokine ELISAs (Bon Opus 
Biosciences) according to the manufacturer’s instructions. All cytokine levels were normalized 
to microglial protein levels determined by BCA assay. 
Nanostring gene expression assay. RNAs were isolated from mouse hippocampus using 
RNeasy Mini Kit (QIAGEN,74104). We performed nCounter multiplexed target profiling of 534 
microglial transcripts with a custom designed microglial gene chip (MG550) using the 
Nanostring nCounter technology (nanostring.com), which allows analysis of up to 800 genes 
from a single sample. Selection of genes was based on genes and proteins specifically or highly 
expressed in adult homeostatic microglia93 plus 150 inflammation-related genes which were 
significantly affected in EAE, APP-PS1 and SOD1 mice94. Using this signature, we generated a 
new version (v3) of Nanostring-based microglia chip termed MG550. For each sample, 100ng 
RNAs were used for hybridization, and all data were normalized to 6 housekeeping genes: Cltc, 
Gapdh, Gusb, Hprt1, Pgk1, and Tubb5. 
Immunofluorescence staining. Two sections (bregma -1.7mm and -2.0mm for CD68, bregma -
2.3mm and -2.6mm for GFAP) from each mouse were used for staining. The sections were 
washed in TBS 3 times, and blocked with 3% BSA in 0.25% TBS-X for 0.5h at RT, followed by 
overnight incubation at 4°C with primary antibodies (CD68: AbD SeroTec, MCA1957, 1:500; 
GFAP: EMD Millipore, MAB3402, 1:2000). The next day, the sections were washed in TBS and 
incubated with fluorescence-labeled secondary antibodies (Molecular probes, 1:500) for 2h at 
RT. The slices were then washed and mounted in prolong gold antifade mounting media 
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(Molecular probes, P36931). Images were taken with an epi-fluorescence microscope at 4x 
magnification and quantified using MetaMorph. 
Western Blot. Mouse cortex was homogenized by sonication in RIPA buffer supplemented with 
Complete and PhosSTOP. Samples were separated by 4–12% NuPAGE (Invitrogen) gel using 
MOPS buffer and transferred to nitrocellulose membranes. Primary antibodies anti-GFAP 
(Millipore, MAB 3402), anti-GAPDH (Abcam, ab9484), anti-α tubulin (Sigma, T5168) and 
HRP-conjugated secondary antibodies (Santa Cruz) were used for detection. Membranes were 
developed using Lumigen TMA6 (GE Healthcare). 
Microfluidic qRT-PCR for astrocytic genes. Total RNA was extracted from mouse cortex 
using the RNeasy Plus kit (Qiagen) and microfluidic qRT-PCR was performed as described87. 
Primary neuron culture and recombinant APOE treatment. Primary neurons were obtained 
from E17 WT mouse (Charles River, #022) fetuses. Hippocampi were dissected in calcium- and 
magnesium-free Hanks' Balanced Salt solution (HBSS) with careful strip of meninges. Tissue 
was digested in HBSS containing 0.25% trypsin (GIBCO #15090-046) and 0.2mg/ml DNase 
(Sigma #DN-25) at 37 °C for 10 min, and was dissociated in HBSS containing 0.4mg/ml DNase 
using a fire-polished Pasteur glass pipette and filtered through a 70-μm nylon mesh. Filtered 
material was pelleted at 1000 g for 5 min, washed with neurobasal medium (Neurobasal + 1x 
B27 + 1x pen/strep + 1x L-glutamine) once, and infected with AAV2/8-synapsin-P301S tau 
virus for 3h on ice. Cells were then pelleted, washed, and plated onto 24-well tissue culture 
plates over glass cover slips that had been coated with 10 µg/ml Poly-L-lysine (PLL, Sigma, 
#P2636) at a density of 20,000 cells/well in neurobasal medium. For all cell culture experiments, 
only the central wells of the plates were used with the peripheral wells filled with 1ml autoclaved 
ddH2O to avoid different rates of medium evaporation during the culture. Recombinant APOE2, 
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APOE3, and APOE4 (Leinco, #A215, A218, A219) were added to the medium (10ug/ml) at the 
time of plating. Neurons were kept for 3 weeks with addition of 200 ul fresh recombinant APOE-
containing medium (10 µg/ml) each well every week, and were then stained with MAP2 
antibody (Thermo Fisher Scientific, #OSM00030W) for analysis and with HT7B (Thermo Fisher 
Scientific, #MN1000B) antibody to confirm tau expression. 
Glia-neuron co-culture. E2, E3, E4 and EKO glia were obtained from P2 pups from the 
respective human APOE KI or APOE KO mice. Cortex was dissected and dissociated in the 
same way as with neuron isolation. Cells were plated in glial medium (DMEM + 10% FBS + 1x 
Pen/strep + 1x Glutamax). Once monolayers were confluent, cells were replated in 24-well plates 
over glass cover slips coated with geltrex (Gibco, #A1413201) at a density of 75,000 cells /well, 
and allowed to grow for 2 days in glia medium. The glia were then washed with 1 ml neurobasal 
medium (Neurobasal + 2% B27 + 1x pen/strep + 1x L-glutamine) and placed in 400 µl 
neurobasal medium before use. Primary neurons expressing P301S tau were prepared as 
described above, and were directly plated on top of the glia at a density of 20,000 cells/well. The 
co-cultures were kept for 3 weeks with addition of 200 µl fresh neurobasal medium each well 
every week. Neurons were then stained with MAP2 antibody (Thermo Fisher Scientific, 
#OSM00030W) for analysis and with HT7B (Thermo Fisher Scientific, #MN1000B) antibody to 
confirm tau expression. 
Immunocytochemistry. Cells were fixed in DPBS containing 4% PFA and 4% sucrose at RT 
for 10 min and permeabilized with 0.3% PBST for 10min. After blocking in 0.1% PBS-Triton X-
100 containing 3% BSA and 3% goat serum for 30min at RT, cells were incubated in primary 
antibodies overnight at 4°C. The next day, cells were washed with 0.1% PBST for 3 times and 
incubated in secondary antibodies for 1h at RT. Cells were then washed 3 times in 0.1% PBST 
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and mounted in prolong gold antifade mounting media (Molecular probes, P36931). Images were 
taken with an epi-fluorescence microscope at 10x magnification and quantified using 
MetaMorph. 
Microglial phagocytosis of injured neurons. Primary microglia were isolated from mix glial 
cultures derived from neonatal WT, APOE KO, APOE2 KI, APOE3KI and APOE4 KI mice. 
Floating microglia were gently flushed off astrocytes with pipet are plated in 24-well plates at a 
density of 200000 cells/well. Isolated microglia were cultured in serum-free medium 
(DMEM/F12 + 1x GlutaMAX + 1x NEAA + 2% ITS-G + 2% B-27 Supplement minus vitamin A 
+ 0.5% N2 Supplement + 200uM 1-Thioglycerol + 5ug/ml Insulin + 50 ng/mL TGF-β + 100 
ng/mL IL-34 + 25 ng/mL MCSF). After cultured for 2 days, the medium was replaced with fresh 
serum-free medium supplemented with two additional maturation factors (100 ng/mL CX3CL1 + 
100 ng/mL CD200) and cultured for 2 days prior to treatment with neurons. Primary neurons 
were cultured separately in 6 well plates at a density of 300000 cells/well. At DIV7, neurons 
were lifted from the plate by pipetting and were injured during this process. Collected neurons 
with labeled with Dil (Thermo Fisher Scientific, #D3911) at 37 degree for 20 min. Labeled 
neurons were washed with neurobasal medium for 3 times and resuspended in microglia serum-
free medium. The neurons were then added to the cultured microglia medium and incubated with 
microglia for 3h or 12h. After incubation, the medium containing injured neurons were removed 
and microglia were washed with PBS for three times before collected with trypsin. Microglia 
were then run through flow cytometry to quantify the amount of intracellular Dil signals. Dil-
labeled neurons were run separately as a control. Small areas of overlapped microglia and 
neuronal cell population were excluded from gating to avoid neuronal contamination in the 




4.3.1 APOE modulates innate immune responses in cultured microglia and 
P301S mice 
To demonstrate that APOE affects microglia-mediated innate immune response, we cultured 
primary microglia isolated from human APOE KI (E2, E3, E4) mice, and stimulated them with  
LPS. We measured the amount of proinflammatory cytokines in the culture medium and 
normalized it to protein concentration of microglia cell lysates. We observed significantly higher 
levels of TNF, IL-1α, and IL-1β produced by APOE4 microglia compared to APOE2 and 
APOE3 microglia (Fig. 4.1a), confirming that APOE4 is associated with an inherently higher 
immune capacity. We then assessed microglial gene expression profiles in 9-month old TE3, 
TE4 and TEKO mice as well as in 9-month old non-tau transgenic APOE KI and APOE KO 
mice using a customized MG550 microglial gene chip. We observed a marked upregulation of 
proinflammatory genes (cluster 1) and a concomitant downregulation of genes involved in 
normal cell function (cluster 2) in TE4 mice, whereas microglia in TEKO mice largely remained 
in a homeostatic state (Fig. 4.1b, c, d). Consistent with this, CD68-positive microglial staining, 
which represents an activated state of microglia, was significantly elevated in TE4 mice, and was 
drastically reduced in TEKO mice (Fig. 4.1e, f). Notably, no pro-inflammatory gene activation 
and no or minimal gene expression differences were observed in 9-month old APOE KI and 
APOE KO mice in the absence of P301S tau (Fig. 4.1b, d) or in 3-month old TE mice (Fig. 4.2), 
indicating the necessity of tau pathology to initiate microglial activation and to enable the APOE 
genotype-dependent effect on microglial activation. Interestingly, p-tau staining patterns were 
highly associated with the microglial activation profile, with type 1 staining displaying the 
lowest, type 2 and type 3 intermediate, and type 4 the strongest microglial activation (Fig. 4.3), 
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suggesting either distinct intrinsic capacities of different p-tau patterns to induce 
neuroinflammation, or distinct toxicities associated with p-tau  
 
Figure 4.1 | APOE strongly modulates microglial activation. a, Cultured primary microglia 
derived from human APOE KI (E2, E3, E4) mouse brains were treated with 1 ng/ml LPS for 24h, 
cytokine levels in the media were measured by ELISA (2 wells/genotype) and were normalized to total 
microglial protein levels, experiment replicated 3 times. b, Nanostring analysis for microglial gene 
expression in 9-month old TE or EKI/EKO mouse hippocampus. Heatmap generated by hierarchical gene 
clustering based on genotypes (Horizontal: 534 microglial genes, vertical: individual mouse samples; 
TE3, TE4, TEKO, E3: n=6, E4: n=4, EKO: n=3). c, Top differentially expressed cluster1 and cluster2 
genes from the heatmap (criteria: fold change TE4 vs. TEKO high to low, p-value <0.01; fold change 
TE4 vs. TE3>1.2). Cluster1: proinflammatory genes, Cluster2: cellular function-related genes 
(metabolism, signaling, transcription, etc.), Cluster3: homeostatic genes/genes below detection. d, z-score 
of genes from cluster 1 or cluster 2 for all groups. Kruskal-Wallis test with Dunn’s multiple comparisons 
test (two-sided) was performed for statistical analysis. e, f, CD68 (activated microglia) staining and 
quantification in 9-month old TE mice (WT: n=5, TE2: n=14, TE3: n=11, TE4: n=17, TEKO: n=10). 
Data expressed as mean ± SEM, One-way ANOVA with Tukey’s post hoc test, two-sided. *p<0.05, 




Figure 4.2 | No or minimal change of microglial gene expression in 3-month old TE mice 
despite significant changes in 9-month old TE mice. a, Nanostring analysis for microglial gene 
expression in 9-month old TE4 mice and 3-month old TE mice (n=5-6). Heatmap generated by 
hierarchical gene clustering based on genotypes (Horizontal: 534 microglial genes, vertical: individual 
mouse samples) b, Z-score of genes from cluster 1 or cluster 2 category. Kruskal-Wallis test with Dunn’s 
multiple comparisons test was performed for statistical analysis. Data expressed as mean ± SEM. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
 
Figure 4.3 | P-tau staining patterns are 
associated with distinct microglial 
activation profiles. a, Heatmap generated 
by hierarchical gene clustering based on p-tau 
staining types for 9-month old TE mice (n=7-
8). b. Principle components analysis (PCA) 
of microglial gene expression profile for p-
tau staining types. c. Z-score of genes from 
cluster 1 or cluster 2 category. Kruskal-
Wallis test with Dunn’s multiple comparisons 
test was performed for statistical analysis.  
Data expressed as mean ± SEM. *p<0.05, 




patterns that cause different levels of neurodegeneration accompanied by different degrees of 
neuroinflammation. 
            Another key cell type in the brain, astrocytes, also play an essential role in 
neuroinflammation. Unlike microglia that are derived from yolk sac precursors, astrocytes 
resemble neurons in that they originate from ectodermal precursors and are not conventional 
immune cells. However, astrocytes are immune-competent. They respond to a wide range of 
brain insults and are activated in a wide range of neurodegenerative diseases including 
Alzheimer’s disease87. Recent studies have identified two distinct types of reactive astrocytes in 
mice depending on the initiating injury: “A1” induced by LPS-elicited inflammation, and “A2” 
induced by ischemia95. These reactive astrocytes are defined by three cassettes of genes: A1-
specifc (inflammation only), A2-specific (ischemia only), and PAN reactive (upregulated in both  
injuries)95. Recent data show that inflammation-induced reactive microglia produce specific  
 
Figure 4.4 | APOE4 leads to robust astrocyte activation whereas the absence of APOE 
attenuates astrocyte activation. a, Microfluidic RT-qPCR for activated astrocytic genes in 9-month 
old TE4 (n=8), TEKO (n=8), and 3-month old TE4 mice (n=6). A1-specific: genes activated only by LPS; 
A2-specific: genes activated only by ischemia; PAN reactive: genes activated by either LPS or ischemia. 
b, GFAP staining in 9-month old TE mice (WT: n=5, TE2: n=14, TE3: n=11, TE4 n=17, TEKO: n=10). 
c, Quantification of area covered by GFAP signal. d, Correlation between GFAP signal and brain volume. 
N=57 biologically independent animals. Pearson correlation analysis (two-sided). Hippocampus: r2=0.66, 
p<0.0001; Piriform cortex: r2=0.68, p<0.0001. e, Western blot for GFAP in 9-month old TE mice (n=3). 
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cytokines (TNF, IL1α, C1q) that can activate 
“A1” astrocytes, which lose many normal  
astrocytic functions, and secret toxic factors 
able to rapidly induce neuronal death87. We 
observed strong activation of “A1” astrocytic 
genes in 9-month TE4 mice, but not in 9-
month TEKO mice or 3-month TE4 mice 
(Fig. 4.4a), nor in 9-month old WT and non-
tau transgenic APOE KI mice (Fig. 4.5). In 
addition, GFAP signal was drastically 
elevated in 9-month old TE4 mice, but not in 
TEKO mice (Fig. 4.4b, c, e). The amount of 
GFAP signal highly correlated with brain 
volume (Fig. 4.4d), suggesting a detrimental 
role of reactive astrocytes in 
neurodegeneration. 
 
4.3.2 APOE regulates glia-mediated neuronal loss in vitro 
Despite the observation that TE4 mice bear significantly higher levels of innate immune 
activation whereas TEKO mice show drastically reduced neuroinflammation correlates well with 
the degree of neurodegeneration seen in these mice, this correlation does not prove that the 
different degrees of neurodegeneration are directly caused by APOE-dependent glial activation.  
 
Figure 4.5 | No activation of A1 astrocytic 
genes in 9-month old non-tau transgenic 
mice. a, Microfluidic RT-qPCR for activated 
astrocytic genes in 9-month old TE4 mice and 9-
month old non-tau transgenic WT and human 
APOE KI mice (n=5). A1-specific: genes activated 
only by LPS; A2-specific: genes activated only by 
ischemia; PAN reactive: genes activated by either 
LPS or ischemia. 
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 To further investigate this possibility, I 
performed in vitro cell culture experiments. I 
co-cultured P301S tau-expressing neurons 
with mixed glia cells consisting of 80-90% 
astrocytes and 10-20% microglia (Fig. 4.6) 
derived from APOE KI or APOE KO mice, 
where the neurons were plated directly on 
top of the glia so that the two cell 
populations are in direct contact with each 
other. Remarkably, the detrimental effect of 
APOE4 on neurodegeneration and the 
protective effect associated with the absence of APOE were robustly recapitulated in the co-
culture system. Drastic neuronal loss occurred in the neuron/E4 glia co-culture, whereas neurons 
co-cultured with EKO glia showed the least injury (Fig. 4.7a, b). Concomitantly, a significantly 
higher level of TNFα was detected in the neuron/E4 co-culture medium whereas minimal TNFα 
levels were detected in the neuron/EKO co-culture medium (Fig. 4.7c), indicating activated glia 
likely played an important role in inducing neuronal death. Interestingly, when P301S tau-
expressing neurons are cultured in the absence of glia cells and treated with recombinant APOE, 
a mild reduction of neuronal cell number and neurite arborization is observed in APOE-treated 
neurons, particularly in APOE4-treated neurons (Fig. 4.7d, e). But the degrees of neuronal 
damage and neuronal loss were much milder compared with the neuron-glia co-cultures, 
suggesting glia-mediated neuroinflammation indeed plays an essential role in exacerbating 
neurodegeneration. The observation that APOE itself is sufficient to induce mild neuronal  
 
Figure 4.6 | Mixed glia culture. Primary mixed 
glia culture isolated from human APOE KI or APOE 
KO mice consisting of 80-90% astrocytes (GFAP+, 




Figure 4.7 | APOE regulates neuronal viability in vitro largely through glia. a, Representative 
images of primary WT neurons infected with AAV2/8-synapsin-P301S human tau co-cultured with 
mixed glia cells (80-90% astrocyte, 10-20% microglia) derived from human APOE KI (E2, E3, E4) and 
APOE KO mouse brain for 3 weeks. Experiment replicated 5 times b, Quantification of neuron number 
and area covered by MAP2 immunostaining signals for co-cultured neurons (4 wells/genotype, 8 random 
images taken/well). c, TNFα levels in the co-culture medium measured by ELISA. d, Representative 
images of primary WT neurons infected with AAV2/8-synapsin-P301S human tau treated with 10µg/ml 
recombinant human APOE for 3 weeks. Experiment replicated twice. e, Quantification of neuron number 
and area covered by MAP2 staining for APOE-treated neurons (3 wells/treatment, 8 random 
images/well).  Data expressed as mean ± SEM, One-way ANOVA with Tukey’s post hoc test, two-sided. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
damage that is potentiated by APOE4, indicates that APOE may be directly involved in inducing 
neurotoxicity in P301S tau-expressing susceptible neurons. Interestingly, APOE has been shown  
to accumulate in damaged neurons of Pick’s Disease96 and in neurofibrillary tangle-bearing 
neurons of AD97, suggesting a potential role of APOE in mediating neurotoxicity under 
pathological conditions, which is an interesting aspect to be further explored in future studies. 
 
4.3.3 The effect of APOE on glia-mediated neuronal loss requires direct 
contact between neurons and glia 
While APOE potently impacts neuronal viability by modulating glial functions, how it does it is 
still not clear. It is likely that APOE, particularly APOE4, enhances microglial activation by 
P301S tau-injured neurons or by the inherently stressful cell culture environment in vitro, 
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resulting in generation of higher levels of neurotoxic substances such as ROS and NO that could 
damage or kill neurons. Activated microglia may further activate the A1-type astrocytes, which 
potentiate the neuronal loss by secreting neurotoxic factors. To assess whether the toxicity comes 
from secreted factors produced by glial cells, I utilized a different neuron-glia co-culture 
approach called the ‘Banker’ method, where the P301S tau-expressing neurons were spatially 
separated from glia in the same culture dish (Fig. 4.8a). Surprisingly, under this condition, the 
effect of APOE on neuronal viability was completely abolished. No apparent neuronal death was 
observed in any of the co-culture groups (Fig. 4.8b). A similar result was obtained when the 
P301S tau-expressing neurons were cultured in glia-conditioned medium (E2, E3, E4, EKO) in  
 
Figure 4.8 | Effects of APOE on glia-mediated neuronal loss require direct neuron-glia 
contact. a, Experimental schemes of different co-culture approaches. Left: Direct contact method. 
Primary neurons are plated directly on top of glia so that neurons are in direct contact with glial cells. 
Right: Banker method. Glia are plated into a dish where four wax dots were fixed to the bottom of the 
dish ahead of time. At the same time, primary neurons are cultured on a separate coverslip. Upon 
attaching to the coverslip, neurons are transferred to the glia dish with the coverslip sitting on top of the 
wax dots. In this scenario, neurons are immersed in the conditioned medium of glia and are exposed to all 
the secreting factors produced by glia, but are not in direct contact with glial cells. b, Representative 
images of primary WT neurons infected with AAV2/8-synapsin-P301S human tau co-cultured with 
mixed glia cells (80-90% astrocyte, 10-20% microglia) derived from human APOE KI (E2, E3, E4) and 
APOE KO mouse brain for 3 weeks using the Banker method. 
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the absence of glial cells (data not shown), indicating that the effect of APOE on glia-mediated 
neuronal loss requires direct contact between neurons and glial cells.  
 
4.3.4 Hypothetic APOE function in glia-mediated neuronal loss 
How does APOE modulate glial function through direct glia-neuron contact that ultimately 
impacts neuron viability? One essential immune function of glial cells leading to neuronal death 
that involves direct neuron-glia contact is phagoptosis, an immune process mediated by 
microglia targeting stressed-but-viable neurons that expose ‘eat-me’ signals on cell surfaces for 
phagocytosis, the process of which kills neurons. Given a protective effect in the absence of 
APOE, I propose a hypothesis that APOE may serve as an opsonin coating the surface of injured 
or dead neurons to promote neuronal phagoptosis by microglia. Neurons express a large number 
of APOE receptors, such as LRP1, HSPGs, and LDLR on cell membranes. Under normal 
conditions, APOE lipoproteins bind to their receptors and deliver cholesterols and lipids to 
neurons via endocytosis. In pathological conditions, such as pathological tau accumulation 
within neurons, neurons may be injured or killed. These jeopardized neurons may have impaired 
cell uptake function, which leads to accumulation of APOE on cell surfaces. Surface-
accumulated APOE may recruit microglia by binding to the triggering receptor expressed on 
myeloid cells 2 (TREM2) expressed by microglia, which is the second strongest AD risk factor 
that has recently been demonstrated to be an APOE receptor98-101. These recruited microglia may 
subsequently phagocytose and kill stressed neurons by recognizing the ‘eat-me’ signals such as 
phosphatidylserine exhibited by these neurons, which exacerbates neuronal loss. Based on this 
hypothesis, microglia will phagocytose more neurons in the presence of APOE and APOE4 may 




Figure 4.9 | APOE regulates microglial phagocytosis of injured neurons. a, A representative 
image of primary microglial culture. b, Primary microglia isolated from WT and APOE KO mice were 
cultured in serum-free medium and incubated with Dil-labeled injured neurons for 3h (3 wells/genotype) 
The amount of phagocytosed neurons in microglia was quantified through flow cytometry. c, Primary 
microglia isolated from human APOE KI mice (E2, E3, E4) were incubated with Dil-labeled injured 
neurons for 12h (3 wells/genotype). The amount of phagocytosed neurons in microglia was quantified 
through flow cytometry. Data expressed as mean ± SEM, One-way ANOVA with Tukey’s post hoc test, 
two-sided. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
          To test this hypothesis, I performed a preliminary experiment where primary microglia 
(Fig. 4.9a) isolated from WT and APOE KO mice were cultured in serum-free medium and 
incubated with injured neurons that were labeled with a fluorescent dye - ‘Dil’. Dil is highly  
lipophilic and can readily incorporates into membranes. The incorporation turns it from being 
weakly fluorescent to a strongly fluorescent dye. After a three-hour incubation, the medium 
containing apoptotic neurons were removed and microglia were washed and collected with 
trypsinization. The amount of fluorescent signals within microglia was then quantified through 
flow cytometry to indicate the level of phagocytosed neurons. Interestingly, WT microglia 
exhibit a higher fluorescent signal compared to APOE KO microglia (Fig. 4.9b), indicating WT 
microglia phagocytose more neurons. In a separate experiment utilizing the same approach to 
analyze the APOE isoform effect, where primary microglia isolated from human APOE KI mice 
(E2, E3, E4) were incubated with Dil-labeled injured neurons for 12h, the E4 microglia 
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displayed a higher intracellular fluorescent signal compared to E2 and E3 microglia (Fig. 4.9c), 
indicating APOE4 enhances neuronal phagocytosis by microglia. While these are very 
preliminary data that need to be further verified with replicating experiments and optimized 
assay conditions, they support the hypothesis that APOE serves as an opsonin in mediating 
microglial immune function. 
          Intriguingly, evidence from previous literature also supports the APOE opsonin 
hypothesis. One study showed that APOE binding to cell surface was significantly enhanced in 
apoptotic N2a cells, a murine neuroblastoma cell line, compared to healthy cells, and cultured 
wildtype microglia phagocytosed significantly more apoptotic N2a cells with APOE added in the 
medium98. In contrast, TREM2-/- microglia showed impaired phagocytosis of apoptotic N2a 
cells98, supporting an APOE-TREM2 axis in mediating microglial phagocytotic function.  
 
4.3.5 Other immunomodulatory functions of APOE in neurodegeneration 
The protective effect of APOE deficiency in neurodegenerative conditions is not restricted to 
tauopathy, but also applies to other neurodegenerative or neuroinflammatory settings102-104. In a 
mouse model of Parkinson’s disease featuring synucleinopathy, APOE deletion significantly 
attenuates the loss of spinal cord motor neurons, delays disease onset, and improves survival103. 
In mouse models of experimental autoimmune encephalomyelitis (EAE), a neuroinflammatory 
disease characterized by infiltration of peripheral immune cells into the CNS that attack myelin 
and cause demyelination and neurodegeneration, APOE ablation attenuates inflammation and 
significantly reduces disease severity102. These evidence suggests a prevalent function of APOE 
in neurodegenerative conditions based on a potential common mechanism in addition to its 
specific effects on individual pathologies. As neuroinflammation is a common feature in 
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neurodegenerative conditions, this shared mechanism is likely linked to APOE’s 
immunomodulatory function. The hypothesis that APOE opsonizes damaged/dead neurons for 
microglial phagoptosis may be a common principle to exacerbate neurodegeneration in 
neurodegenerative conditions. On the other hand, recent progresses on microglial research 
indicates another possibility.  
          Initial characterization of microglial cell polarization into pro-inflammatory ‘M1’ and 
reparative ‘M2’ phenotypes was based on the M1/M2 macrophage classification105. 
Macrophages acquire an M1 phenotype in response to interferon γ (IFNγ) and synthesize toxic 
substances, such ROS, NO, and lysosomal enzymes to kill microbes. By contrast, M2 
macrophages are induced by interleukin-4 (IL-4) and express enzymes for collagen synthesis and 
fibrosis to promote tissue repair. Likewise, activated microglia are divided into an M1 
phenotype, characterized by upregulation of inflammatory genes such as TNF and IL1β, and an 
M2 phenotype, characterized by the expression of pro-repair genes such as arginase 1 (Arg1) and 
chitinase-like 3 (Chi3l3, also known as Ym1)106. However, this nomenclature is now deemed 
inaccurate as accumulating evidence has revealed a broad diversity of macrophage activation 
statuses and shown that macrophages show remarkable plasticity to change phenotypes in 
response to environmental cues107,108.  
            In neurodegenerative diseases, the precise gene signatures of microglia that mediate 
pathology-and neurodegeneration-associated sterile inflammation have not been clearly 
elucidated. Recent single-cell RNA-seq data identified a two-stage microglial cell activation 
process that occurs during disease progression in an Aβ-depositing mouse model, where the 
transition from the first to the second stage is determined by TREM2109. The end-stage activated 
microglia appear to display a conserved core-expression profile harbouring certain degrees of 
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diversity across individual disease phenotypes104,109. The core expression profile is likely induced 
by neuronal cell death or damage, whereas distinct pathologies may contribute to the diversity. 
The common disease-associated microglial cell signature was defined by different groups as the 
‘microglial neurodegenerative’ (MGnD) phenotype104 or the ‘disease-associated microglia’ 
(DAM) phenotype109. This signature is characterized by a suppression of microglial homeostatic 
genes, and highlighted by an induction of pro-inflammatory genes as well as genes involved in 
microglial phagocytotic function targeting degenerated/injured neurons and amyloid 
plaques104,109. The MGnD phenotype can largely be recapitulated by injecting apoptotic neurons 
into mouse brain parenchyma, where the subset of microglia that are activated to phagocytose 
apoptotic neurons show a similar molecular phenotype to the MGnD phenotype104. The MGnD 
microglia can also be activated via intracerebral administration of kainic acid that induces 
neuronal cell death104, supporting the idea that neuronal death and damage determines the central 
microglial cell gene signature in neurodegenerative diseases. Importantly, although the microglia 
that phagocytose apoptotic neurons share many molecular signatures with lipopolysaccharide 
(LPS) and IFNγ-stimulated M1 microglia, they also exhibit significant differences, such as 
contrasting gene expression patterns of secreted phosphoprotein 1(Ssp1), CC-chemokine ligand 3 
(Ccl3), and early growth response 1(Egr1). But the most distinguishing difference is that the 
expression of Apoe — the hallmark gene of the MGnD phenotype that has been found to be 
upregulated in microglia in all currently-assessed neurodegenerative diseases — is suppressed in 
M1 microglia. In addition, certain classical M2 microglial cell markers, such as Arg1 and Ym1, 
are also induced in microglia that phagocytose apoptotic neurons, indicating a unique microglial 
activation profile in neurodegenerative diseases that is distinct from the M1/M2 classification104 
(Table 4.1).  
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          Crucially, APOE deletion is found to prevent full acquisition of the microglial 
neurodegenerative phenotype with suppression of key MGnD genes and restoration of 
homeostatic microglial genes104. This may prohibit disease-associated microglia from being fully  
developed to carry out their pro-inflammatory and phagocytotic functions, and hinder their 
capacity to kill and damage neurons via phagoptosis or inflammatory mechanisms, which may 
underlie the protective effect of APOE deficiency in various neurodegenerative settings. 
Supporting this view, in a facial nerve axotomy model, global APOE deletion or conditional 
ablation of APOE in microglia reduces neuronal loss in the facial motor nucleus after axotomy of 
the facial nerve104. However, how APOE deficiency dampens MGnD microglial activation is still 
not clear and is an intriguing direction for future studies. 
 
Table 4.1 | Comparison of different microglial cell phenotypes. * Inconclusive 




TREM2 is another risk gene for late-onset Alzheimer’s disease and is second only to APOE in 
terms of the magnitude of its effects. The most common TREM2 variant R47H increases 
Alzheimer’s disease risk by 2- to 3-fold110,111. TREM2 is a cell surface receptor of the 
immunoglobulin superfamily that is expressed by tissue macrophages, such as bone osteoclasts, 
CNS microglia, alveolar macrophages, peritoneal macrophages and intestinal macrophages112. 
Upon activation, TREM2 signals through an adaptor protein DNAX-activation protein 12 
(DAP12) to promotes cell anabolic metabolism113, survival113,114, proliferation115 and 
phagocytosis115,116. 
          In the CNS, TREM2 critically regulates microglial functions in disease. Similar to APOE 
that determines MGnD microglial activation, TREM2 is also required for acquisition of the 
neurodegenerative microglial phenotype. TREM2 deletion in APPPS1-21 or superoxide 
dismutase 1 (SOD1) mice results in APOE downregulation and a similar suppression of core 
inflammatory MGnD genes and restoration of homeostatic genes104. Targeting TREM2 signaling 
in the facial nerve axotomy model ameliorates neuronal loss104, and ablation of TREM2 in 
tauopathy mice attenuates neuroinflammation and neurodegeneration117. These phenotypes 
closely resembling the effects of APOE deletion suggest that APOE likely shares the same 
pathways as TREM2 in regulating microglial function in neurodegeneration. APOE may activate 
the neurodegenerative microglial phenotype through interaction with TREM2 that triggers 
TREM2 signaling in microglia, it may also serve as an opsonin coating cell surfaces of 
damaged/dead neurons that recruit microglia for neuronal phagoptosis by binding to TREM2. 
The working model for the immunomodulatory function of APOE in regulating 
neurodegeneration is summarized in Fig. 4.10. While this model features tauopathy, the 




Figure 4.10 | A working model for the immunomodulatory function of APOE in regulating 
neurodegeneration in tauopathy. a, In Alzheimer’s disease or tauopathy, intracellular accumulation 
of pathological tau in neurons causes neuronal injury or neuronal death. These jeopardized neurons may 
have impaired cell uptake function, which results in accumulation of APOE on neuronal cell surfaces. 
Surface-coated APOE may serve as an opsonin to recruit microglia for neuronal phagoptosis by binding 
to TREM2 expressed by microglia, thus exacerbating neurodegeneration. In addition, the presence of 
APOE enables full activation of neurodegenerative microglia (DAM/MGnD) that harbor a 
proinflammatory profile in addition to a high phagocytotic activity. These activated microglia produce 
inflammatory cytokines that induce A1 astrocytes, which kill/damage neurons via secreting neurotoxic 
factors and loss of neurotrophic functions. The large amounts of ROS/NO generated during microglia 
activation can also induce oxidative stresses that directly injure/kill neurons. Furthermore, the 
inflammatory milieu can also induce tau hyperphosphorylation by activating tau kinases through IL-1 
signaling, thus exacerbating tau pathology that further aggregate neurodegeneration. b, In the absence of 
APOE, microglia largely stay in a more homeostatic status, generating less neurotoxic substances, which 
results in less neuron damage or death. In addition, loss of APOE as a potential opsonin for microglia-
mediated neuronal phagoptosis may also contribute to preservation of intact neurons. 
 
4.3.7 Effect of microglial depletion on neurodegeneration in the tauopathy 
mouse model 
To provide concrete evidence for microglial function in neurodegeneration and in mediating 
APOE’s effects on neurodegeneration, I decided to deplete microglia in TE4 and TEKO mice to  
64 
 
assess how microglial deficiency affects neurodegeneration in the presence and absence of 
APOE. Current microglial depletion techniques are based on either genetic manipulation or  
pharmacological treatment. A common genetic approach utilizes transgenic mice that express 
herpes simplex virus thymidine kinase (HSVTK) under the CD11b promoter118. HSVTK encodes 
a suicide protein that phosphorylate ganciclovir (GCV), a guanosine analog, to a 
monophosphorylated form, which is further converted by host kinases to toxic GCV-triphosphate 
that induces premature DNA chain termination and cell apoptosis. Therefore, GCV 
administration in CD11b-HSVTK transgenic mice results in depletion of cells of the myeloid 
origin, including microglia. However, this approach has multiple disadvantages. First, systemic 
GCV treatment results in low efficiency of microglia depletion and induces lethal myelotoxicity 
that need to be resolved by bone marrow transplantation119; second, direct intracerebral delivery 
of GCV achieves higher efficiency of microglial depletion, but the surgery can cause brain 
damage and the treatment cannot go longer than 4 weeks due to lethal microhemorrhages 
induced by GCV119; third, GCV treatment damages the blood brain barrier120 which may 
generate experimental artifacts. In contrast, pharmacological treatment through oral delivery of 
drugs that block the colony-stimulating factor 1 receptor (CSF1R) signaling constitutes a 
noninvasive and a highly effective approach to deplete microglia. CSF1R is expressed primarily 
by macrophages, microglia, and osteoclasts, and its signaling is critical for microglial 
proliferation, differentiation, and survival. PLX3397, a small molecule that potently and 
selectively inhibit CSF1R and c-Kit, was reported to be able to deplete 90% microglia within 7 
days when administered as a supplement in mouse chow121. Importantly, long-term treatment of 
PLX3397 does not induce notable toxicity in mice122. Therefore, I utilized this approach and 
treated TE4 and TEKO mice as well as their age-matched non-tau transgenic counterparts with 
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PLX3397-supplemented chow from 186 days to 285 days, a critical time window for the 
development of neurodegeneration in this mouse model.  
          Preliminary characterization showed that PLX3397 treatment via mouse chow potently 
depleted microglia in the mouse brain. Seven-day treatment resulted in ~90% reduction of 
microglia whereas by twenty-one days, microglia were almost completely eliminated (Fig. 4.11). 
A bonus finding on top of this study is that the ingredients of the base chow strongly affect the  
 
Figure 4.11 | PLX3397 treatment eliminates microglia in the brain. a, b, Representative images 
and quantification of Iba1-labeled microglia at 7 days after treatment with PLX3397-supplemented AIN 
chow (400mg drug/kg chow) in 4.5-month APOE4 KI male mice. n=2-3 mice per group. b, 
Representative images and quantification of Iba1-labeled microglia at 21 days after treatment with 
PLX3397-supplemented AIN chow (400mg drug/kg chow) in 4.5-month male APOE4 KI mice. n=2-3 
mice per group Quantification of area covered by Iba1 signal. Data expressed as mean ± SEM, One-way 




Figure 4.12 | Both chow ingredients and mouse genders affect PLX3397-mediated 
microglial depletion. a, b, Three to four months old female TE4 mice were treated with either 
PLX3397-AIN chow (300mg drug/kg chow) or PLX3397-Purina chow (300mg drug/kg chow) together 
with their respective control chows for 7 days (n=2-3). The brains were stained with Iba1 and quantified 
for Iba1 covered area. b, c, Three to four months old female and male TE4 mice were treated with 
PLX3397-AIN chow and control AIN chow for 7 days (n=2-3). Microglia were quantified through Iba1 
staining. Data expressed as mean ± SEM, One-way ANOVA with Tukey’s post hoc test (two-sided). 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
drug efficiency. PLX3397 supplemented in a grain-based chow (Purina 5053) showed markedly 
reduced microglial-depletion efficiency compared with PLX3397 supplemented in a purified 
ingredient chow (AIN-76A) (Fig. 4.12a, b, Table 4.2a). This effect was in part due to a poorer 
capacity of the grain-based chow to assimilate the drug during chow manufacturing (Table 4.2a), 
leading to a slightly lower level of drug uptake by the mice compared to the AIN chow (20% 
difference, Table 4.2a). However, plasma PLX3397 concentration, which highly correlates with 
microglial depletion efficiency, was drastically reduced in mouse treated with PLX3397-Purina  
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chow compared to mice treated with PLX3397-AIN chow (55% difference, Table 4.2a), 
indicating the chow ingredients impact PLX3397 absorption or clearance. Interestingly, there 
also appeared to be a gender effect, with male mice accumulated twice as much PLX3397 in the 
plasma compared to females when treated with PLX3397-AIN chow, even though their drug 
uptake is similar (Table 4.2b). Correspondingly, male mice demonstrated a significantly higher 
level of microglial elimination than female mice (Fig. 4.12b, c, Table 4.2b). This result suggests 
that females may have a higher capacity to resist immune disturbances and to maintain a  
homeostatic immune status. This trait may underlie the protective effect observed in female  
P301S mice, which show delayed disease onset compared to male mice. Given this observation  
 
Table 4.2 | Effects of base chow and gender on microglial depletion parameters. a, 
Comparison of base chow ingredients in affecting drug incorporation rate in diet, drug uptake, plasma 
drug concentration and microglial depletion rate in 3-4 month old TE4 female mice treated with 
PLX3397-AIN chow (300mg drug/kg chow) or PLX3397-Purina chow (300mg drug/kg chow) for 7 days. 
b, Comparison of gender effects on drug uptake, plasma drug concentration and microglial depletion rate 




and an early disease onset in male P301S mice, only male mice were used for this study. 
          Consistent with our previous observation, by 285 days, TE4 mice showed marked brain 
atrophy whereas TEKO mice showed much more preserved brain (Fig. 4.13). Impressively, 
microglial depletion in TE4 mice rescued brain atrophy to the level of a normal non-tau 
transgenic mouse brain (Fig. 4.13), indicating that microglia-mediated neuroinflammation plays 
a fundamental role in driving neurodegeneration. Intriguingly, the rescuing effect of microglial 
depletion on neurodegeneration occurred only in the presence of APOE (i.e., only in TE4 mice, 
but not in TEKO mice), and in the absence of microglia, TE4 and TEKO mice showed the same 
brain volume independent of APOE status (Fig. 4.13), indicating that the effect of APOE on 
neurodegeneration in the tauopathy mouse model primarily lies in APOE’s immunomodulatory 
function in affecting microglia-mediated neuroinflammation. As discussed in previous sessions, 
APOE controls MGnD microglial activation, and may opsonize activated microglia for their 
 
Figure 4.13 | Microglial depletion in tauopathy mice rescues neurodegeneration in an 
APOE-dependent manner. a, Representative brain sections of 285 days old TE4, TEKO, E4, and 
EKO male mice treated with control AIN chow or PLX3397-supplemented AIN chow (400mg drug/kg 
chow) from day 186 to day 285. b, Quantification of hippocampal volume for these mice (TE4-control: 
n=21, TE4-drug: n=17, TEKO-control: n=19, TEKO-drug: n=18, E4-control: n=12, E4-drug: n=6, EKO-
control: n=13, EKO-drug: n=6). Data expressed as mean ± SEM, One-way ANOVA with Tukey’s post 
hoc test (two-sided). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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phagoptosis of injured/dead neurons, which may be key mechanisms connecting APOE to 
microglia-mediated neurodegeneration. Additional investigations to prove the “APOE opsonin” 
hypothesis and to elucidate how APOE regulates MGnD microglial activation are ongoing to 
further understand the mechanisms. In addition, we are also addressing important questions 
including the direct effect of APOE on tau pathogenesis in the absence of microglia-mediated 
neuroinflammation, the status and function of astrocytes in neurodegeneration independent of 
microglia, effects of APOE and PLX3397 on peripheral immune cells in the blood circulation 
that may indirectly impact neurodegeneration via affecting neuroinflammation, etc. These 
analyses will lead us towards a comprehensive understanding of how APOE, tau, and 
neuroinflammation interacts with each other to cause neurodegeneration. 
 
4.4 Discussion 
4.4.1 Differential immunomodulatory functions of APOE in infectious and 
neurodegenerative conditions 
Neuroinflammation has been increasingly recognized to play an essential role in 
neurodegenerative diseases. The association of APOE4 with enhanced immunoreactivity has 
been consistently documented in infectious diseases or upon direct LPS stimulation90-92,123. How 
APOE4 achieves this is not well understood. Evidence shows that lipid rafts play an essential 
role in immune activation by serving as platforms for signaling complex assembly (Fig. 4.14); 
hence minor intervention on membrane lipids such as cholesterol loading or efflux is sufficient to 
induce membrane remodeling and subsequent signal transduction124. Higher retention of 
cholesterol in lipid rafts due to lack of the cholesterol efflux transporters ABCA1 or ABCG1, 




Figure 4.14 | APOE-mediated cholesterol efflux affects immune cell activation by 
regulating cell membrane lipid contents. Lipid rafts that contain high concentrations of cholesterol 
and glycosphingolipids serve as platforms for the assembly of immune signaling complexes on cell 
membranes, and therefore are enriched with immune receptors such as TLR4. The cholesterol content on 
cell membrane critically regulates lipid raft formation, which would further affect immune activation. 
APOE lipoprotein can induce cholesterol efflux from cell membrane via the ABCA1 transporter, 
therefore reducing cholesterol levels on the plasma membrane, which inhibit lipid raft formation and 
immune activation. 
conditions125, whereas myeloid cell surface-bound APOE promotes cholesterol efflux in a cell-
autonomous fashion (Fig. 4.14) to inhibit myelopoiesis126. APOE4 is reported to be less effective 
than APOE3 in inducing cholesterol efflux from macrophages 127, which causes cholesterol 
accumulation on cell membranes90,127. This mechanism has been proposed to explain the higher 
immune reactivity associated with APOE4. Alternatively, other research shows that as a lipid 
carrier, APOE can directly bind to LPS, which also contains a lipid component, and redirect it to 
liver for uptake and clearance by liver parenchyma cells, hence reducing the amount of 
circulating LPS and attenuates LPS-induced immune responses128. Given that domain interaction 
in APOE4 affects the lipid binding function of APOE, it is likely that APOE4 has impaired LPS-
binding and neutralizing capacity compared with other APOE isoforms, resulting in a higher 
level of immune responses. Regardless of the mechanism, multiple evidence supports an 
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immune-suppressing role of APOE in LPS stimulation or bacterial infection. For example, 
APOE-deficient mice are shown to behave similarly to APOE4-targeted replacement (APOE4-
TR) mice in response to intracerebroventricular LPS stimulation with enhanced gliosis and 
cytokine production compared with APOE2-TR and APOE3-TR mice92. APOE-deficient mice 
are also more susceptible to infection- and LPS-induced lethality with amplified TNF production 
in the serum129-131. 
          Contrary to LPS stimulation where APOE deletion amplifies the immune response, under 
neurodegenerative or neuroinflammatory conditions, APOE deficiency attenuates 
inflammation18,23,102,104 and disease severity18,102,103. As mentioned in early sections, APOE 
ablation protects against neurodegeneration in mouse models of tauopathy, Parkinson’s disease, 
EAE, and facial nerve axotomy, indicating multidomain immunomodulatory functions of APOE 
in regulating infectious diseases and neurodegenerative diseases. These functional differences 
are likely caused by different mechanisms. On the one hand, APOE may reduce the excitability 
of immune cells towards LPS stimulation by modulating lipid raft content on cell membranes, or 
through direct APOE-LPS interactions to neutralize LPS toxicity; on the other hand, under 
neurodegenerative conditions, APOE is required for intact functionality of MGnD microglia. 
APOE deletion prevents full acquisition of the microglial neurodegenerative phenotype with 
suppression of key MGnD genes104, and therefore may prohibit disease-associated microglia 
from being fully developed to carry out their pro-inflammatory and phagocytotic functions. In 
addition, APOE may serve as an opsonin to promote neuronal phagoptosis by MGnD microglia 
through interaction with TREM2, therefore exacerbating neurodegeneration.  
          Our observation that microglia depletion in tauopathy mice almost fully restored brain 
integrity provides concrete evidence for a dominating role of microglia-mediated 
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neuroinflammation in inducing neurodegeneration. In the absence of microglia, the effect of 
APOE on neurodegeneration is gone, indicating that APOE regulates neurodegeneration 
primarily by modulating microglial functions. Mechanistically, how APOE triggers microglia to 
depolarize into the neurodegenerative phenotype distinct from conventional M1/M2 microglia is 
a central question to be solved. Opsonization may be another major mechanism through which 
APOE regulates microglia-mediated neurodegeneration, but needs to be clearly demonstrated. 
 
4.4.2 The APOE-TREM2 axis in modulating Aβ pathology in addition to its 
role in neurodegeneration 
The APOE-TREM2 axis that is essential for regulating neurodegeneration also appears be 
involved in the regulation of Aβ pathogenesis. Microglia have long been observed to cluster 
around Aβ plaques in postmortem AD brains and in Aβ-depositing mouse models. Unlike non-
plaque-associated microglia that retain a more homeostatic phenotype109,132, plaque-associated 
microglia show major alterations in their molecular signatures and constitute the population of 
‘disease-associated microglia’ in the setting of Aβ-deposition109. TREM2 expression is 
specifically upregulated in these plaque-associated microglia during plaque deposition, and was 
essential for promoting microglial cell association with plaques133-138. TREM2 haplodeficiency, 
ablation, or the TREM2R47H mutation leads to a significant reduction of plaque-associated 
microglia compared to their TREM2-sufficient counterparts133-138. This is likely in part due to 
TREM2 being as an Aβ receptor that facilitate microglial association with plaques139. 
Corresponding to a loss of microglial enclosure around plaques, TREM2-deficient Aβ-depositing 
mice develop significantly enlarged and less compact plaques containing longer and diffuse star-
shaped amyloid fibrils that project from loosely packed cores137,138 (Fig. 4.15a). Such 




Figure 4.15 | Deficiency of APOE or TREM2 leads to similar amyloid plaque phenotypes. a, 
During Aβ plaque deposition, the presence of TREM2 enables activation of the DAM/MGnD microglia and 
allows them to associate with amyloid plaques and trim Aβ fibrils on the edge to compact the plaque. 
Plaque-associated microglia also serve as a barrier between the plaque and surrounding tissues to reduce 
Aβ-induced toxicity to neurites. TREM2 deficiency hinders full acquisition of the DAM/MGnD microglial 
phenotype and significantly reduces the number of plaque-associated microglia. This results in enlarged 
amyloid-β plaques with wispy fibre-like structures projecting from loosely packed cores and greater 
neuritic dystrophy in close vicinity. b, Microglial clustering around Aβ plaques for plaque trimming and 
insulation is also strictly regulated by APOE. The presence of APOE activates DAM/MGnD microglia and 
promotes microglial association with plaques to perform plaque-trimming and -compacting functions. In 
addition, APOE is abundantly present in amyloid plaques and may opsonize plaques for microglial 
phagocytosis through APOE-TREM2 interactions. The absence of APOE prevents DAM/MGnD microglial 
activation and loses its opsonization function, leading to reduction of plaque-associated microglia and 
formation of diffuse plaques accompanied by enhanced neuritic dystrophy, similar to the phenotype of 
TREM2 deficiency. 
dystrophy in close vicinity137,138 (Fig. 4.15a), indicating that plaque-associated microglia perform 
plaque trimming and compacting functions that help to restrict plaque growth, and that these 
cells serve as a barrier to limit plaque-induced neuronal toxicity. Indeed, plaque-associated 
microglia have been shown to contain plaque-derived materials109,138, indicating their capability 
to phagocytose plaque components. Importantly, APOE ablation in APPSwePSEN1dE9 or 
APPPS1-21 mice also impairs microglial association with plaques and leads to enlarged plaques 
exhibiting wispy fibre-like structures projecting from loosely packed cores that are accompanied 
by significantly elevated neuritic dystrophy in the vicinity140, which recapitulates the phenotype 
observed in TREM2-deficient Aβ-depositing mice137,138 (Fig. 4.15). The shared phenotypes 
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between APOE deficiency and TREM2 deficiency on Aβ pathology in addition to their common 
effects on neurodegeneration strongly suggest an APOE–TREM2 axis linking APOE to 
microglial function. APOE may function upstream of TREM2 to activate the MGnD microglia 
that possess a high phagocytotic capacity targeting either damaged/dead neurons or plaques, 
likely by binding to TREM2 and inducing TREM2 signaling. In addition, APOE may serve as an 
opsonin by binding to TREM2 to enhance microglial phagocytosis of amyloid plaques in 
addition to targeting injured/dead neurons for phagoptosis, as APOE is abundantly present in 
amyloid plaques as a significant plaque component19,20. This intriguing model needs to be 



























Chapter 5: Targeting APOE as a therapeutic 















The protective effect of APOE deficiency on neurodegeneration in the setting of tauopathy leads 
to the possibility of targeting APOE as a therapeutic approach for treating tauopathy. While 
multiple approaches can be utilized to reduce APOE levels at either transcriptional or 
translational levels, one convenient way to target APOE with high efficiency is to manipulate 
APOE receptors to enhance APOE uptake and degradation. APOE binds primarily to a group of 
receptors known as the low density lipoprotein receptor (LDLR) family, which contains over 10 
receptors including LDLR, LRP1, apolipoprotein receptor 2 (APOER2), very low density 
lipoprotein receptor (VLDLR), and others4. All these receptors contain a single transmembrane 
domain with a short cytoplasmic tail. The extracellular regions of these receptors contain three 
characteristic modules: ligand-binding repeats (also called complement-type repeats), epidermal 
growth factor (EGF) repeats and YWTD-containing β-propeller domains4. LDLR is the smallest 
receptor and the prototype of this family. It together with LRP1 constitute the two major types of 
APOE metabolic receptors in the brain. LDLR is predominantly expressed in glia whereas LRP1 
is primarily expressed in neurons and to a lesser degree in glia. Systemic ablation of Ldlr128 or 
conditional Lrp1 knockout in mouse forebrain neurons141 increases APOE levels in the brain, 
whereas overexpression of LDLR142 markedly reduces brain APOE levels, indicating these 
receptors regulate APOE metabolism and can be utilized to modulate APOE levels. The large 
size of LRP1 makes it difficult to be manipulated for experimental purposes. Although functional 
LRP1 minireceptors have been generated143, overexpressing mLPR2 - the minireceptor that 
preserves the ligand binding and internalization capacity of LRP1- does not alter APOE levels144. 
Therefore, LDLR serves as an appropriate target for APOE modulation. 
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          LDLR transgenic mice have been generated previously. These mice overexpress over five-
fold of murine LDLR in both neurons and astrocytes, leading to a ten-fold reduction of soluble 
APOE in the brain142. By crossing LDLR transgenic mice to P301S mice, I generated 
P301S+LDLR+ and P301S+LDLR- littermates and assessed them at 9 months of age. 
 
5.2 Experimental procedures 
Animals. LDLR transgenic mice on a B6/CBA background were generated in house 
previously142. P301S tau transgenic mice (The Jackson Laboratory, #008169) on a B6 
background expressing human P301S 1N4R tau driven by PrP promoter were crossed to LDLR 
transgenic mice to generate P301S+LDLR+ and P301S+LDLR- littermates. APOE knockout mice 
(C57BL/6) were purchased from the Jackson Laboratory (#002052) and were crossed to P301S 
mice to generate P301S mE/- mice, which were further crossed to APOE knockout mice or 
wildtype mice (C57BL/6, Charles River Laboratories, #027) to generate P301S mE/mE, P301S 
mE/- and P301S APOEKO mice. Only male mice were used for this study. 
Volumetric analysis, immunohistochemistry, and brain extraction were performed as 
described in chapter 2 and chapter 3.  
ELISA. Human tau, ptau and murine APOE ELISAs were performed as described previously70. 
For coating antibodies, Tau5 (gift from L. Binder, Northwestern University, Chicago, IL) was 
used for human tau ELISA. HJ14.5 (in house) was used for ptau ELISA and HJ6.2 (in house) 
was used for murine APOE ELISA. For detection antibodies, biotinylated HT7 (Thermo Fisher 
Scientific, MN1000B) was used for human tau ELISA. Biotinylated AT8 (Thermo Fisher 





5.3.1 LDLR overexpression in P301S mice attenuates neurodegeneration and 
tau pathology 
 
Figure 5.1 | LDLR overexpression in P301S mice attenuates neurodegeneration. a, 
Representative images of 9-month old P301S and P301S/LDLR mouse brain. b, c, Quantification of brain 
weight and brain volume for these mice. (P301S: n=21, P301S/LDLR: n=17). Data expressed as mean ± 
SEM, One-way ANOVA with Tukey’s post hoc test (two-sided). *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. Ent: Entorhinal cortex, Piri: Piriform cortex. 
Volumetric analysis of 9-month old P301S and P301S/LDLR mice showed that LDLR 
overexpression significantly attenuated neurodegeneration in the piriform/entorhinal cortex and  
hippocampus (Fig. 5.1a, b). In addition, brain weight was significantly increased in 
P301S/LDLR mice compared to P301S mice (Fig. 5.1c). Subsequent assessment of tau 






Figure 5.2 | LDLR 
overexpression in P301S mice 
shifts ptau staining patterns 
towards the ones associated 
with less brain damage. 
Distribution of p-tau staining 
patterns between 9-month old 
P301S and P301S/LDLR mice 
type3 and type4 - patterns that are associated with more severe brain damage - towards type1, an 
early disease pattern associated with the most preserved brain (Fig. 5.2). 
          Biochemical analysis confirmed a 10-fold reduction of soluble APOE in the RAB fraction 
and also some reduction of insoluble APOE in the formic acid fraction in 9-month P301S/LDLR 
mice compared to P301S mice (Fig. 5.3a). Despite the marked APOE reduction, human tau 
levels were not altered in any fractions (Fig. 5.3b). However, notable reduction of ptau levels 
were observed in RAB and RIPA fraction upon LDLR overexpression (Fig. 5.3c). Interestingly, 
although no change of absolute human tau levels was observed, APOE level correlated with less 
soluble tau and a higher level of insoluble tau (Fig. 5.3d). In addition, APOE level strongly  
correlated with ptau levels in all fractions (Fig. 5.3e), indicating that APOE may promote ptau  




Figure 5.3 | LDLR overexpression in P301S mice reduces ptau level without altering tau 
levels. a-c, Human P301S tau, ptau, and murine APOE levels in 9-month P301S and P301S/LDLR 
mouse brains were measured by ELISA in RAB, RIPA and 70% FA fractions respectively (P301S: n=17, 
P301S/LDLR: n=16). d, Correlation between APOE and human tau levels in RAB, RIPA and FA 
fractions. e, Correlation between APOE and ptau levels in RAB, RIPA and FA fractions. Data expressed 
as mean ± SEM, One-way ANOVA with Tukey’s post hoc test (two-sided) was used for statistical 




To confirm that the change of ptau levels in P301S/LDLR mice was mediated by APOE, but not 
an artifact due to LDLR overexpression, we generated a separate cohort of P301S mice 
expressing two alleles, one allele, or no murine APOE by crossing P301S mice to APOE 
knockout mice. We observed exactly the same pattern of ptau reduction in RAB and RIPA 
fractions with in P301S mice expressing one allele or no APOE (Fig. 5.4), supporting the role of 
APOE in mediating ptau pathogenesis. How APOE promotes ptau generation is not clear. APOE 
may enhance tau hyperphosphorylation through direct interaction with tau that alters 
pathological tau conformation and toxicity, which may further boost cellular stress that induces 
tau phosphorylation. On the other hand, given an essential role of neuroinflammation in inducing 




Figure 5.4 | APOE deficiency in P301S mice results in ptau reduction similar to the effect of 
LDLR overexpression. Ptau levels in 9-month old P301S mE/mE, P301S mE/-, and P301S -/- mouse 
brains were measured by ELISA (P301S mE/mE: n=13, P301S mE/-: n=13, P301S -/-: n=13). Data 
expressed as mean ± SEM, One-way ANOVA with Tukey’s post hoc test (two-sided) was used for 




As a proof-of-concept study, lowering APOE levels by overexpressing its metabolic receptor 
LDLR attenuates neurodegeneration and tau pathology, indicating that APOE-based therapy may 
constitute an effective way to treat tauopathy. Interestingly, although LDLR overexpression 
reduces APOE levels, it bears fundamental differences from APOE-deficient mice in that LDLR+ 
mice still produce APOE so that any cell-autonomous APOE functions are preserved. The 
observation that LDLR overexpression confer similar protective effects on neurodegeneration as 
APOE ablation indicates that the extracellular pool of APOE plays an essential role in 
neurodegeneration. This is in line with the APOE opsonin hypothesis where extracellular APOE 
serves as an opsonin to enhance microglial phagoptosis of stressed neurons. On the other hand, 
it’s not clear how APOE controls MGnD microglial activation. It’s likely that extracellular 
APOE stimulates MGnD microglial activation by interacting with TREM2 and initiates 
microglial signaling, yet an alternative possibility is that microglia-synthesized APOE activates 
MGnD microglia in a cell-autonomous fashion, in which case lowering extracellular APOE may 
not prevent MGnD microglial activation. Preliminary analysis of our single nuclei RNAseq data 
from P301S and WT mice shows that in the diseased brain, APOE expression is drastically 
upregulated in microglia, but only shows minor changes in astrocytes, indicating that microglia-
derived APOE, which has key differences from astrocyte-derived APOE in their lipid contents, is 
the one that is involved in neurodegeneration. In fact, the population of APOE serving as 
opsonins may exclusively come from microglia-derived APOE, in which case the specific 
composition of APOE particles may serve as unique landmarks to facilitate microglial 
recruitment. This specific APOE may also act as a signaling molecule to notify microglia for 
disease onset and to prepare them for immune functioning by activating the MGnD signature. 
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Interestingly, although LDLR overexpression attenuates neurodegeneration in P301S mice, the 
pattern of protection is different from that of TEKO mice. While not a single case of severe 
neurodegeneration harboring type4 tau was observed in approximately 40 TEKO mice that were 
assessed, a portion of P301S /LDLR mice still develop severe neurodegeneration with type4 tau, 
although the ratio is lower with LDLR overexpression. This could be simply due to a partial 
rescue effect as a result of remaining APOE in the brain, or the MGnD microglia was still 
activated in P301S/LDLR mice in a cell-autonomous manner independent of extracellular APOE 
reduction, which exacerbated neurodegeneration compared to TEKO mice. Still it could be a 
gain of toxic function from LDLR overexpression. Therefore, a cleaner approach to reduce 
APOE levels would be to directly target APOE mRNAs. This would reduce APOE levels 
without introducing additional confounding factors. One commonly adopted and clinically 
relevant approach to target mRNAs is to use antisense oligonucleotides (ASOs), which are short 
pieces of synthetic, chemically modified DNA sequences designed to bind complementary RNA 
targets to facilitate their degradation. Our ongoing experiments with APOE ASO treatment in 
TE4 mice would be an important supplement to the LDLR overexpression scheme. 
 
5.5 Concluding remarks and future directions 
APOE, the strongest genetic risk factor for Alzheimer’s disease, has long been considered to 
affect AD through modulating Aβ pathology. However, this mechanism alone is insufficient to 
explain APOE’s robust impact on AD given the poor correlation between Aβ pathology and AD-
associated neurodegeneration and cognitive impairment. In this work, we uncovered a significant 
function of APOE in regulating neurodegeneration in the setting of tauopathy independent of 
APOE’s effect on Aβ pathogenesis. We found APOE4 significantly exacerbates tau-mediated 
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neurodegeneration compared to APOE2 and APOE3, whereas APOE deficiency is strongly 
neuroprotective. The effects of APOE on neurodegeneration are likely derived from two aspects: 
a direct role of APOE in regulating tau pathogenesis, which induces neurotoxicity in a cell 
autonomous manner; and an immunomodulatory function of APOE to regulate neuronal viability 
by modulating neuroinflammation in a non-cell autonomous fashion. Although our microglia-
depletion experiment suggests that regulation of microglia-mediated neuroinflammation by 
APOE plays a dominant role in APOE-dependent neurodegeneration, the effects of APOE on tau 
pathogenesis cannot be neglected, as pathological tau and tau-induced neuronal injury likely 
serve as the initial trigger of neuroinflammation. We found that APOE specifically interacts with 
a high-molecular-weight form of tau. This interaction may enable APOE to regulate tau 
pathogenesis, for instance, by affecting tau structure, modification, aggregation, seeding, or 
clearance. We found APOE promotes tau phosphorylation and correlates with higher levels of 
insoluble tau. In addition, APOE4 leads to higher levels of tau accumulation compared to 
APOE2, APOE3 and APOE deficiency, likely by affecting tau autophagy. In characterizing tau 
pathology in the P301S mouse model, we established a new pathological tau categorization 
system based on hippocampal ptau staining patterns. These patterns serve as sensitive indicators 
of neurodegeneration, and may also represent distinct tau species. The fact that APOE affects 
ptau patterns also points to a likelihood that APOE may participate in shaping tau conformation 
and regulate tau species formation.  
          On the other hand, once neuroinflammation is initiated by pathological tau accumulation 
and associated neural injury, it becomes a driving force of neurodegeneration. APOE has 
previously been implicated in systemic inflammation during infection. APOE4 is associated with 
higher levels of immune responses upon conventional immune stimulation (such as LPS 
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stimulation) compared to APOE2 and APOE3, and the ɛ4 allele has been hypothesized to be 
acquired during human evolution to confer initial advantages in pathogen resistance. Here we 
introduced the concept of APOE’s immunomodulatory function implicated in infectious diseases 
to the field of neurodegeneration. We found TE4 mice demonstrated significantly higher levels 
of microglial and astrocytic activation compared to TE2 and TE3 mice, whereas APOE 
deficiency reduced glial activation relative to the presence of APOE. Through in vitro glia-
neuron co-culture, we demonstrated that glia cells directly contributed to neuronal death. We 
found that glia-mediated neuronal loss requires direct cell-cell contact between glia and neurons, 
and this process is strongly regulated by APOE. The presence of APOE, particularly APOE4, 
significantly exacerbates neuronal loss. In vivo, depleting microglia rescued neurodegeneration 
in TE4 mice, but showed no impact on TEKO mice, highlighting an APOE-dependent microglial 
function in neurodegeneration. We proposed an “APOE opsonin” hypothesis where APOE 
serves as an opsonin coating the surfaces of sick neurons that show impaired APOE endocytosis, 
and recruits activated microglia by binding to TREM2 expressed on microglia to facilitate 
microglia-mediated neuronal phagoptosis. This hypothesis is supported by our preliminary in 
vitro observation that microglia phagocytose more dead neurons in the presence of APOE 
compared to the absence of APOE, but needs to be proved with further experiments. In addition 
to coating jeopardized neurons, APOE may also serve as an opsonin binding to amyloid plaques, 
which regulates microglia-mediated plaque trimming and phagocytosis. Aside from hypothetic 
opsonization functions, APOE has lately been shown to be a critical determinant of microglial 
polarization into the neurodegenerative phenotype under neurodegenerative conditions. APOE 
ablation leads to incomplete microglial activation, yielding semi-activated microglia that fail to 
acquire the neurotoxic MGnD phenotype featuring inflammatory and phagocytotic microglial 
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functions. APOE-dependent regulation of microglial reactivity likely relies on APOE’s capacity 
to modulate lipid contents on microglial cell membranes, which controls lipid raft remodeling 
that plays a critical role in immune cell activation. However, detailed mechanisms beneath 
APOE-controlled microglial activation still await elucidation. We think the immunomodulatory 
function of APOE constitutes a common mechanism regulating neurodegeneration in a variety of 
neurodegenerative disorders. Our findings, together with emerging evidence from other groups, 
suggest a re-evaluation of the role of APOE in AD and other neurodegenerative diseases.  
          Given an essential role of APOE in regulating tau-mediated neurodegeneration, we 
targeted APOE as a therapeutic approach to treat tauopathy. We found a protective effect on 
neurodegeneration with LDLR overexpression, which lowered soluble APOE by 10-fold and 
most likely targets the extracellular APOE pool, suggesting extracellular APOE plays a role in 
neurodegeneration. However, the rescue effect is much milder than that of APOE ablation, 
suggesting that intracellular APOE, particularly microglia-derived APOE that shoots up sharply 
in disease, may cell-autonomously regulate microglial immune function that is crucial in 
neuroinflammation-induced neurodegeneration. Emerging evidence suggests that APOE particles 
produced in various cell types are composed of different lipid contents and may have distinct 
functions. Yet the detailed composition and function of APOE lipoprotein coming from different 
sources still await elucidation.    
          Our findings that APOE directly regulates neurodegeneration, neuroinflammation and tau 
pathogenesis independent of its well-known role in Aβ pathogenesis, add new perspective to AD 
pathogenesis and open up new directions in AD research. Here I summarize the important 
questions to be solved in future studies. 
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1. Tau, instead of Aβ, is directly associated with neurodegeneration. However, how pathological 
tau induces neurotoxicity is still unclear. Distinct tau strains have been identified in AD and 
other primary tauopathy patients. How tau conformation in relate to its function is linked to 
different aspects of tau neurotoxicity adds another layer of complexity to the question. 
Traditionally it was believed that tau seeding is detrimental. However, we found that compared 
to certain forms of tau, the tau species that harbor higher seeding activity is associated with less 
neurodegeneration, indicating that under certain conditions, tau seeding may be less detrimental, 
likely by trapping more toxic forms of tau. Importantly, we found that tau seeding is not 
equivalent to insoluble tau formation, the concept of which have been confused in the past. The 
tau species harboring higher seeding capacity is in fact associated with relatively high solubility, 
whereas certain tau species showing low seeding capacities turn out to be more insoluble and are 
associated with more severe brain damage. We think tau solubility may be a better indicator of 
brain damage than tau seeding activity. Interestingly, we found that tau seeding capacity strongly 
correlates with thioflavin S signal (data not shown), a marker for β-sheet structure. The tau 
species possessing high seeding activity stains highly positive for ThioS, whereas other tau 
species harboring low seeding capacities stains low or negative for ThioS, indicating that β-sheet 
structure is a determinant for tau seeding activity. ThioS has been commonly used to stain for tau 
pathology. However, our findings indicate that ThioS staining may only reveal the pathological 
tau species that present high seeding activity, but may skip other tau species that are more 
insoluble with higher neurotoxicity. Therefore, a detailed characterization of tau species and the 
type of neurotoxicity they confer would be critical in understanding the mechanism of tau-
mediated neurodegeneration. On top of this, understanding how APOE affects tau pathology and 
tau-mediated neurotoxicity, either through direct APOE-tau interactions, or via indirect 
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mechanisms, would provide important insight on APOE’s function in neurodegeneration in the 
setting of tauopathy. 
2. Neuroinflammation plays a critical role in driving neurodegeneration. Although multiple 
hypotheses have been proposed as to how neuroinflammation causes neurodegeneration, none of 
them have been evidently proved. To date, it’s still unclear how neurons die under inflammatory 
milieu, either through apoptosis, necrosis, pyroptosis or other pathways. It would be critical to 
understand the concrete neuronal pathways being affected by neuroinflammation that lead to 
neuronal death in order to design targeted therapies to prevent neuronal loss. 
3. Microglia and astrocytes constitute the two major cell populations in the brain mediating 
neuroinflammation in neurodegenerative diseases. However, their respective roles in inducing 
neurodegeneration are not well understood. Microglia are conventional immune cells reserving 
all innate immune cell properties and may play a dominant role in neuroinflammation including 
pathology sensing, cytokine secretion, and phagocytosis, etc. Unlike microglia that are derived 
from yolk sac myeloid precursors, astrocytes resemble neurons in that they originate from 
ectodermal precursors and are not conventional immune cells. In physiological conditions, the 
predominant functions of astrocytes are to provide nutritional and growth support to neurons to 
maintain their survival and function, and to regulate extracellular ion and neurotransmitter 
concentrations to maintain environmental homeostasis. Under pathological conditions, astrocytes 
are immune-competent and can secret inflammatory cytokines upon activation. They can also 
crosstalk with microglia and produce neurotoxic factors. However, in general, the neurotoxic 
effects of reactive astrocytes may principally lie in their loss of neural support functions in 
addition to their gain of neurotoxic function with unique secreted factors, which mechanistically 
could be different from microglia-mediated neurodegeneration. Dissecting out the respective 
89 
 
roles of microglia and astrocytes in neurodegeneration would provide critical mechanistic 
insights into understanding neuroinflammation-induced neurodegeneration. Our ongoing 
microglia-ablation experiment in tauopathy mice for the first time clearly demonstrated a critical 
role of microglia in driving neurodegeneration. However, how microglia achieve this, either 
solely by itself though its innate immune functions independent of astrocytes, or via crosstalk 
with astrocytes is not clear. Specific functions of astrocytes in neurodegeneration are even less 
understood. These questions need to be comprehensively addressed in future studies.  
4. Despite the resemblance of CNS microglia to macrophages in peripheral tissues in a variety of 
aspects, microglial activation signature in neurodegenerative diseases bears unique features and 
is different from macrophage activation profiles in systemic inflammation. Studies in this area 
have just begun. Deeper characterization of disease-associated microglia signatures and 
functions with cutting-edge technologies such as single cell RNAseq and mass cytometry will be 
key to understanding the role of microglia-mediated neuroinflammation in neurodegeneration, 
and to directing neuroinflammation-based therapies. While chronic neuroinflammation can 
exacerbate neurodegeneration, initial microglial activation at an early disease stage may help 
clear pathological proteins and prevent their accumulation. Specific reprogramming of microglia 
to increase the clearance of pathological proteins without amplifying inflammatory stress or 
targeting neurons are promising fields in future research. 
5. The potent immunomodulatory function of APOE may be a principle mechanism through 
which APOE regulates neurodegeneration in various neurodegenerative diseases. Based on our 
findings and inference from literature, we proposed two mechanisms in respect to how APOE 
may modulate microglial functions: 1) by modulating microglial cell membrane lipid content to 
affect microglial immune reactivity 2) by serving as an opsonin regulating microglial 
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phagocytotic functions. Yet additional evidence is needed to support these hypotheses. Future 
studies to further investigate mechanisms underlying APOE’s immunomodulatory function 
would be essential to understand APOE’s role in neurodegeneration. Research can focus on 
connecting APOE-dependent lipid profiles with microglial immune activation signatures, and 
further investigation of the APOE-TREM2 axis in regulating microglial functions. 
6. Our single nuclear RNAseq data show that under neurodegenerative conditions, brain APOE 
expression goes up in general, but uniquely surge in microglia many folds over other cell types, 
suggesting cell-type dependent APOE function in disease. As lipids perform both nutritional and 
immunoregulatory functions, APOE lipoprotein produced in different cell types may carry 
distinct lipid contents and serve different functions. Future studies investigating the composition 
and function of APOE derived from different cellular source, such as microglia, astrocytes, 
neurons and peripheral tissues, via APOE conditional knockout or overexpression in these cell 
types, would be critical to fundamentally understand the multifaceted roles of APOE in 
neurodegeneration. 
7. The blood-brain barrier separates the brain parenchyma from the blood circulation. Therefore, 
neuroinflammation in neurodegenerative diseases is predominantly characterized of innate 
immunity mediated by the brain-resident glia cells. However, accumulating evidence suggests 
crosstalk between the CNS and the periphery that may play an essential role in brain 
pathogenesis. In particular, recent studies showing connections of gut microbiota with AD145-147 
and PD148 pathogenesis and microglial functions145,149 strongly suggest signaling exchange 
between the periphery and the CNS, likely mediated by soluble factors that can cross the blood-
brain barrier. The periphery-CNS immune connection and its role in brain pathogenesis and 
neurodegeneration is a promising field that should be investigated in depth in future studies. On 
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the other hand, many neurodegenerative diseases begin with disruption of proteostasis. This 
process, once initiated, cannot currently be self-resolved and will inevitably lead to pathological 
protein accumulation that eventually progresses to neurodegeneration. One reason for the failure 
of the brain to effectively maintain proteostasis is likely due to the lack of adaptive immunity in 
brain parenchyma compared with peripheral tissues, which jeopardize the brain’s clearance 
machinery. Boosting immune activity in the brain to increase waste clearance under homeostatic 
or pathological status without damaging neurons by introducing adaptive immunity into the brain, 
such as pathology-directed antibody treatment or engineered T cell-based strategies may be 
promising fields that can be worked out with caution to avoid potential side effects in the future. 
8. Therapeutic studies should follow up new mechanistic discoveries to treat neurodegenerative 
diseases. Traditionally, immunotherapies targeting pathological proteins such as Aβ, and lately 
tau, have been widely adopted. However, the results are not very satisfactory. Given a 
dominating effect of microglia-mediated neuroinflammation in driving neurodegeneration in the 
presence of APOE, future attention should be focused on targeting neuroinflammation or APOE. 
PLX3397, the CSF1R inhibitor that deplete microglia, may serve as an effective drug to prevent 
neurodegeneration and slow down disease progression. With better mechanistic insights in the 
future, targeted drugs designed to inhibit neurodegenerative microglial activation may be an 
optimal choice. APOE-based therapies to lower down APOE mRNA or protein levels, such as 
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